5,973 results on '"Uehara, A."'
Search Results
2. Immunohistochemical investigation of biomarkers for predicting adipose tissue invasion in oral squamous cell carcinoma
- Author
-
Hiroki Otagiri, Yibing Han, Eiji Kondo, Makiko Kawamoto, Takeshi Uehara, Atsushi Takizawa, Hirokazu Tanaka, Hironori Sakai, Hiroshi Kurita, Takahiko Gibo, Shin-ichi Yamada, and Masao Hashidume
- Subjects
Pathology ,medicine.medical_specialty ,Buccal fat pad ,medicine.diagnostic_test ,business.industry ,Adipose tissue ,Computed tomography ,Fat pad ,Pathology and Forensic Medicine ,stomatognathic diseases ,Otorhinolaryngology ,medicine ,Immunohistochemistry ,Surgery ,Basal cell ,Oral Surgery ,business ,Preoperative imaging ,Predictive biomarker - Abstract
The purpose of the present study was to identify histological biomarkers that could be used to predict adipose tissue invasion by oral squamous cell carcinoma (OSCC). The medical records and preoperative computed tomography scans of patients with primary OSCC with suspected buccal fat pad invasion were retrospectively reviewed, and an immunohistochemical study of candidate predictive biomarkers of adipose tissue invasion (α-SMA, E-cadherin, N-cadherin, FABP4, Col VI, and MMP-11) was carried out. Thirty OSCC patients whose tumors were suspected to be in contact with the buccal fat pad based on preoperative imaging were included in this study. Of these, infiltrative adipose tissue invasion was histopathologically confirmed in 6 patients (20.0 %). The significant higher immunoreactivity of candidate predictive biomarkers was detected in the tumor-buccal fat pad contact area compared to in the tumor surface area.(Pearson’s correlation coefficient test: α-SMA: 0.422, p
- Published
- 2022
3. Comparison of the oncological outcomes of stenting as a bridge to surgery and surgery alone in stages II to III obstructive colorectal cancer: a retrospective study
- Author
-
Masaru Komatsu, Akira Iwaya, Hiroaki Uehara, Motoharu Hirai, Toshiyuki Yamazaki, and Hitoshi Kameyama
- Subjects
Curative resection ,medicine.medical_specialty ,business.industry ,Colorectal cancer ,Decompression ,medicine.medical_treatment ,Perforation (oil well) ,Gastroenterology ,Stent ,Retrospective cohort study ,medicine.disease ,Surgery ,Medicine ,Bridge to surgery ,business ,Pathological - Abstract
Purpose: We evaluated the oncological outcomes of bridge to surgery (BTS) using stent compared with surgery alone for obstructive colorectal cancer.Methods: Consecutive patients who underwent curative resection for stages II to III obstructive colorectal cancer at our institution from January 2009 to March 2020, were registered retrospectively and divided into 43 patients in the BTS group and 65 patients in the surgery alone group. We compared the surgical and oncological outcomes between the 2 groups.Results: Stent-related perforation did not occur. One patient in whom the stent placement was unsuccessful underwent emergency surgery with poor decompression (clinical success rate, 97.7%). The pathological characteristics were not significantly different between the groups. The following surgical outcomes in the BTS group were superior to those in the surgery alone group; nonemergency surgery (P
- Published
- 2022
4. Deep Generative Model Using Unregularized Score for Anomaly Detection With Heterogeneous Complexity
- Author
-
Kazuki Sato, Takashi Matsubara, Kuniaki Uehara, Kenta Hama, and Ryosuke Tachibana
- Subjects
Models, Statistical ,Computer science ,business.industry ,Anomaly (natural sciences) ,Pattern recognition ,Statistical model ,Regularization (mathematics) ,Computer Science Applications ,Image (mathematics) ,Human-Computer Interaction ,Generative model ,Control and Systems Engineering ,Anomaly detection ,Artificial intelligence ,Electrical and Electronic Engineering ,Set (psychology) ,business ,Software ,Information Systems - Abstract
Accurate and automated detection of anomalous samples in an image dataset can be accomplished with a probabilistic model. Such images have heterogeneous complexity, however, and a probabilistic model tends to overlook simply shaped objects with small anomalies. The reason is that a probabilistic model assigns undesirable lower likelihoods to complexly shaped objects, which are nevertheless consistent with the current set standards. This difficulty is critical, especially for a defect detection task, where the anomaly can be a small scratch or grime. To overcome this difficulty, we propose an unregularized score for deep generative models (DGMs). We found that the regularization terms of the DGMs considerably influence the anomaly score depending on the complexity of the samples. By removing these terms, we obtain an unregularized score, which we evaluated on toy datasets, two in-house manufacturing datasets, and on open manufacturing and medical datasets. The empirical results demonstrate that the unregularized score is robust to the apparent complexity of given samples and detects anomalies selectively.
- Published
- 2022
5. Genetic background in late-onset sensorineural hearing loss patients
- Author
-
Shin-ichi Usami, Jun Yokoi, Sayaka Katsunuma, Natsumi Uehara, Daisuke Yamashita, Ken-ichi Nibu, Shin-ya Nishio, Akinobu Kakigi, and Takeshi Fujita
- Subjects
Pediatrics ,medicine.medical_specialty ,medicine.diagnostic_test ,Hearing loss ,MYO7A ,business.industry ,Hearing Loss, Sensorineural ,medicine.disease ,Pedigree ,Frameshift mutation ,Phenotype ,Retinitis pigmentosa ,otorhinolaryngologic diseases ,Genetics ,Etiology ,medicine ,Humans ,Sensorineural hearing loss ,Stickler syndrome ,medicine.symptom ,Hearing Loss ,business ,Genetic Background ,Genetics (clinical) ,Genetic testing - Abstract
Genetic testing for congenital or early-onset hearing loss patients has become a common diagnostic option in many countries. On the other hand, there are few late-onset hearing loss patients receiving genetic testing, as late-onset hearing loss is believed to be a complex disorder and the diagnostic rate for genetic testing in late-onset patients is lower than that for the congenital cases. To date, the etiology of late-onset hearing loss is largely unknown. In the present study, we recruited 48 unrelated Japanese patients with late-onset bilateral sensorineural hearing loss, and performed genetic analysis of 63 known deafness gene using massively parallel DNA sequencing. As a result, we identified 25 possibly causative variants in 29 patients (60.4%). The present results clearly indicated that various genes are involved in late-onset hearing loss and a significant portion of cases of late-onset hearing loss is due to genetic causes. In addition, we identified two interesting cases for whom we could expand the phenotypic description. One case with a novel MYO7A variant showed a milder phenotype with progressive hearing loss and late-onset retinitis pigmentosa. The other case presented with Stickler syndrome with a mild phenotype caused by a homozygous frameshift COL9A3 variant. In conclusion, comprehensive genetic testing for late-onset hearing loss patients is necessary to obtain accurate diagnosis and to provide more appropriate treatment for these patients.
- Published
- 2022
6. Clinical Outcome of Closure of a Small Atrial Septal Defect in a Patient with Pulmonary Arterial Hypertension
- Author
-
Atsushi Yao, Masahiko Umei, Masae Uehara, Katsura Soma, Issei Komuro, Akihito Saito, and Toshiro Inaba
- Subjects
Right heart catheterization ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,General Medicine ,medicine.disease ,behavioral disciplines and activities ,Pulmonary hypertension ,Atrial septal defects ,Cardiac magnetic resonance imaging ,Internal medicine ,mental disorders ,Internal Medicine ,Cardiology ,Medicine ,In patient ,Closure (psychology) ,business ,Clinical decision - Abstract
The closure of small/coincidental atrial septal defects (ASDs) in patients with pulmonary arterial hypertension (PAH) has been described in recent major guidelines as useless or even contraindicated. We confirm the effectiveness of "Treat and Repair" for ASD closure through one patient diagnosed with idiopathic PAH with small ASD, under careful observation with right heart catheterization and cardiac magnetic resonance imaging. The clinical decision concerning the closure of ASD with PAH should be made not only by referring to the guidelines but also by evaluating the benefits and risks specific to that case.
- Published
- 2022
7. BCS1L mutations produce Fanconi syndrome with developmental disability
- Author
-
China Nagano, Akira Otake, Hiroyuki Mishima, Yasutoshi Koga, Hisato Suzuki, Koh-ichiro Yoshiura, Kei Murayama, Tomohiko Yamamura, Kojima Ishii Kanako, Kenjiro Kosaki, Satoshi Murata, Kazumoto Iijima, Koji Nagatani, Nana Sakakibara, Tomoko Horinouchi, Yuichi Mushimoto, Yuko Ichimiya, Tomoko Uehara, and Kandai Nozu
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,Mitochondrial Diseases ,BCS1L ,Developmental Disabilities ,Cardiomyopathy ,Compound heterozygosity ,Bioinformatics ,Electron Transport Complex III ,hemic and lymphatic diseases ,Genetics ,Humans ,Medicine ,Child ,Gene ,Genetics (clinical) ,Paediatric kidney disease ,business.industry ,nutritional and metabolic diseases ,Fanconi syndrome ,Metabolic acidosis ,medicine.disease ,Mitochondrial respiratory chain complex III ,Mutation ,ATPases Associated with Diverse Cellular Activities ,business ,Hypophosphatemia - Abstract
Fanconi syndrome is a functional disorder of the proximal tubule, characterized by pan-aminoaciduria, glucosuria, hypophosphatemia, and metabolic acidosis. With the advancements in gene analysis technologies, several causative genes are identified for Fanconi syndrome. Several mitochondrial diseases cause Fanconi syndrome and various systemic symptoms; however, it is rare that the main clinical symptoms in such disorders are Fanconi syndrome without systematic active diseases like encephalomyopathy or cardiomyopathy. In this study, we analyzed two families exhibiting Fanconi syndrome, developmental disability and mildly elevated liver enzyme levels. Whole-exome sequencing (WES) detected compound heterozygous known and novel BCS1L mutations, which affect the assembly of mitochondrial respiratory chain complex III, in both cases. The pathogenicity of these mutations has been established in several mitochondria-related functional analyses in this study. Mitochondrial diseases with isolated renal symptoms are uncommon; however, this study indicates that mitochondrial respiratory chain complex III deficiency due to BCS1L mutations cause Fanconi syndrome with developmental disability as the primary indications.
- Published
- 2022
8. Neutrophil-to-lymphocyte ratio is associated with survival and sentinel lymph node positivity in invasive cutaneous squamous cell carcinoma: A retrospective study
- Author
-
Takuya Maeda, Azusa Hiura, Tomoe Nakagawa, Rino Toyoshima, Jiro Uehara, and Koji Yoshino
- Subjects
Oncology ,medicine.medical_specialty ,Prognostic factor ,Skin Neoplasms ,Cutaneous squamous cell carcinoma ,Multivariate analysis ,Neutrophils ,Sentinel Lymph Node Biopsy ,business.industry ,fungi ,Sentinel lymph node ,Retrospective cohort study ,Dermatology ,Prognosis ,Predictive factor ,Internal medicine ,Carcinoma, Squamous Cell ,medicine ,Humans ,Biomarker (medicine) ,Lymphocytes ,Sentinel Lymph Node ,Neutrophil to lymphocyte ratio ,business ,Retrospective Studies - Abstract
Background The neutrophil-to-lymphocyte ratio (NLR) is a known prognostic biomarker for survival and is predictive of sentinel lymph node (SLN) positivity in some cancers. However, its usefulness as a prognostic biomarker for cutaneous squamous cell carcinoma (cSCC) has not been fully investigated. Objective Our objective was to investigate the relationship between the NLR and the disease-specific survival and SLN positivity in patients with cSCC. Methods In this single-center retrospective case series, we analyzed patients with cSCC who underwent blood tests prior to the initiation of treatment at our oncology hospital. The relationship between the patients’ clinical characteristics (including the NLR) and the disease-specific survival and SLN positivity was evaluated using univariate and multivariate analyses. Results An elevated NLR was an independent prognostic factor for poor disease-specific survival and a predictive factor for SLN positivity. Limitations Limitations include the small number of participants and selection bias due to the large proportion of high-risk cases in our patient population. Conclusion NLR is a useful biomarker in cSCC because it is simple to measure and can predict prognosis.
- Published
- 2022
9. Simultaneous pelvic exenteration and liver resection for primary rectal cancer with synchronous liver metastases: results from the PelvEx Collaborative
- Author
-
Kelly, M. E., Aalbers, A. G. J., Abdul Aziz, N., Abecasis, N., Abraham‐Nordling, M., Akiyoshi, T., Alberda, W., Albert, M., Andric, M., Angenete, E., Antoniou, A., Auer, R., Austin, K. K., Aziz, O., Baker, R. P., Bali, M., Baseckas, G., Bebington, B., Bednarski, B. K., Beets, G. L., Berg, P. L., Beynon, J., Biondo, S., Boyle, K., Bordeianou, L., Bremers, A. B., Brunner, M., Buchwald, P., Bui, A., Burgess, A., Burger, J. W. A., Burling, D., Burns, E., Campain, N., Carvalhal, S., Castro, L., Caycedo‐Marulanda, A., Chan, K. K. L., Chang, G. J., Chew, M. H., Chong, P. C., Christensen, H. K., Clouston, H., Codd, M., Collins, D., Colquhoun, A. J., Corr, A., Coscia, M., Coyne, P. E., Creavin, B., Croner, R. S., Damjanovic, L., Daniels, I. R., Davies, M., Davies, R. J., Delaney, C. P., Denost, Q., Deutsch, C., Dietz, D., Domingo, S., Dozois, E. J., Duff, M., Eglinton, T., Enrique‐Navascues, J. M., Espin‐Basany, E., Evans, M. D., Fearnhead, N. S., Flatmark, K., Fleming, F., Frizelle, F. A., Gallego, M. A., Garcia‐Granero, E., Garcia‐Sabrido, J. L., Gentilini, L., George, M. L., Ghouti, L., Giner, F., Ginther, N., Glynn, R., Golda, T., Griffiths, B., Harris, D. A., Hagemans, J. A. W., Hanchanale, V., Harji, D. P., Helewa, R. M., Heriot, A. G., Hochman, D., Hohenberger, W., Holm, T., Hompes, R., Jenkins, J. T., Kaffenberger, S., Kandaswamy, G. V., Kapur, S., Kanemitsu, Y., Kelley, S. R., Keller, D. S., Khan, M. S., Kiran, R. P., Kim, H., Kim, H. J., Koh, C. E., Kok, N. F. M., Kokelaar, R., Kontovounisios, C., Kristensen, H. Ø., Kroon, H. M., Kusters, M., Lago, V., Larsen, S. G., Larson, D. W., Law, W. L., Laurberg, S., Lee, P. J., Limbert, M., Lydrup, M. L., Lyons, A., Lynch, A. C., Mantyh, C., Mathis, K. L., Margues, C. F. S., Martling, A., Meijerink, W. J. H. J., Merkel, S., Mehta, A. M., McArthur, D. R., McDermott, F. D., McGrath, J. S., Malde, S., Mirnezami, A., Monson, J. R. T., Morton, J. R., Mullaney, T. G., Negoi, I., Neto, J. W. M., Nguyen, B., Nielsen, M. B., Nieuwenhuijzen, G. A. P., Nilsson, P. J., O’Connell, P. R., O’Dwyer, S. T., Palmer, G., Pappou, E., Park, J., Patsouras, D., Pellino, G., Peterson, A. C., Poggioli, G., Proud, D., Quinn, M., Quyn, A., Radwan, R. W., van Ramshorst, G. H., Rasheed, S., Rasmussen, P. C., Regenbogen, S. E., Renehan, A., Rocha, R., Rochester, M., Rohila, J., Rothbarth, J., Rottoli, M., Roxburgh, C., Rutten, H. J. T., Ryan, É. J., Safar, B., Sagar, P. M., Sahai, A., Saklani, A., Sammour, T., Sayyed, R., Schizas, A. M. P., Schwarzkopf, E., Scripcariu, V., Selvasekar, C., Shaikh, I., Hellawell, G., Shida, D., Simpson, A., Smart, N. J., Smart, P., Smith, J. J., Solbakken, A. M., Solomon, M. J., Sørensen, M. M., Steele, S. R., Steffens, D., Stitzenberg, K., Stocchi, L., Stylianides, N. A., Sumrien, H., Sutton, P. A., Swartking, T., Taylor, C., Tekkis, P. P., Teras, J., Thurairaja, R., Toh, E. L., Tsarkov, P., Tsukada, Y., Tsukamoto, S., Tuech, J. J., Turner, W. H., Tuynman, J. B., Vasquez‐Jimenez, W., Verhoef, C., Vizzielli, G., Voogt, E. L. K., Uehara, K., Wakeman, C., Warrier, S., Wasmuth, H. H., Weber, K., Weiser, M. R., Wheeler, J. M. D., Wild, J., Wilson, M., de Wilt, J. H. W., Wolthuis, A., Yano, H., Yip, B., Yip, J., Yoo, R. N., van Zoggel, D., Winter, D. C., Kelly, M. E., Aalbers, A. G. J., Abdul Aziz, N., Abecasis, N., Abraham‐nordling, M., Akiyoshi, T., Alberda, W., Albert, M., Andric, M., Angenete, E., Antoniou, A., Auer, R., Austin, K. K., Aziz, O., Baker, R. P., Bali, M., Baseckas, G., Bebington, B., Bednarski, B. K., Beets, G. L., Berg, P. L., Beynon, J., Biondo, S., Boyle, K., Bordeianou, L., Bremers, A. B., Brunner, M., Buchwald, P., Bui, A., Burgess, A., Burger, J. W. A., Burling, D., Burns, E., Campain, N., Carvalhal, S., Castro, L., Caycedo‐marulanda, A., Chan, K. K. L., Chang, G. J., Chew, M. H., Chong, P. C., Christensen, H. K., Clouston, H., Codd, M., Collins, D., Colquhoun, A. J., Corr, A., Coscia, M., Coyne, P. E., Creavin, B., Croner, R. S., Damjanovic, L., Daniels, I. R., Davies, M., Davies, R. J., Delaney, C. P., Denost, Q., Deutsch, C., Dietz, D., Domingo, S., Dozois, E. J., Duff, M., Eglinton, T., Enrique‐navascues, J. M., Espin‐basany, E., Evans, M. D., Fearnhead, N. S., Flatmark, K., Fleming, F., Frizelle, F. A., Gallego, M. A., Garcia‐granero, E., Garcia‐sabrido, J. L., Gentilini, L., George, M. L., Ghouti, L., Giner, F., Ginther, N., Glynn, R., Golda, T., Griffiths, B., Harris, D. A., Hagemans, J. A. W., Hanchanale, V., Harji, D. P., Helewa, R. M., Heriot, A. G., Hochman, D., Hohenberger, W., Holm, T., Hompes, R., Jenkins, J. T., Kaffenberger, S., Kandaswamy, G. V., Kapur, S., Kanemitsu, Y., Kelley, S. R., Keller, D. S., Khan, M. S., Kiran, R. P., Kim, H., Kim, H. J., Koh, C. E., Kok, N. F. M., Kokelaar, R., Kontovounisios, C., Kristensen, H. Ø., Kroon, H. M., Kusters, M., Lago, V., Larsen, S. G., Larson, D. W., Law, W. L., Laurberg, S., Lee, P. J., Limbert, M., Lydrup, M. L., Lyons, A., Lynch, A. C., Mantyh, C., Mathis, K. L., Margues, C. F. S., Martling, A., Meijerink, W. J. H. J., Merkel, S., Mehta, A. M., Mcarthur, D. R., Mcdermott, F. D., Mcgrath, J. S., Malde, S., Mirnezami, A., Monson, J. R. T., Morton, J. R., Mullaney, T. G., Negoi, I., Neto, J. W. M., Nguyen, B., Nielsen, M. B., Nieuwenhuijzen, G. A. P., Nilsson, P. J., O’Connell, P. R., O’Dwyer, S. T., Palmer, G., Pappou, E., Park, J., Patsouras, D., Pellino, G., Peterson, A. C., Poggioli, G., Proud, D., Quinn, M., Quyn, A., Radwan, R. W., van Ramshorst, G. H., Rasheed, S., Rasmussen, P. C., Regenbogen, S. E., Renehan, A., Rocha, R., Rochester, M., Rohila, J., Rothbarth, J., Rottoli, M., Roxburgh, C., Rutten, H. J. T., Ryan, É. J., Safar, B., Sagar, P. M., Sahai, A., Saklani, A., Sammour, T., Sayyed, R., Schizas, A. M. P., Schwarzkopf, E., Scripcariu, V., Selvasekar, C., Shaikh, I., Hellawell, G., Shida, D., Simpson, A., Smart, N. J., Smart, P., Smith, J. J., Solbakken, A. M., Solomon, M. J., Sørensen, M. M., Steele, S. R., Steffens, D., Stitzenberg, K., Stocchi, L., Stylianides, N. A., Sumrien, H., Sutton, P. A., Swartking, T., Taylor, C., Tekkis, P. P., Teras, J., Thurairaja, R., Toh, E. L., Tsarkov, P., Tsukada, Y., Tsukamoto, S., Tuech, J. J., Turner, W. H., Tuynman, J. B., Vasquez‐jimenez, W., Verhoef, C., Vizzielli, G., Voogt, E. L. K., Uehara, K., Wakeman, C., Warrier, S., Wasmuth, H. H., Weber, K., Weiser, M. R., Wheeler, J. M. D., Wild, J., Wilson, M., de Wilt, J. H. W., Wolthuis, A., Yano, H., Yip, B., Yip, J., Yoo, R. N., van Zoggel, D., Winter, D. C., Kelly, ME, Aalbers, AGJ, Aziz, NA, Abecasis, N, Abraham-Nordling, M, Akiyoshi, T, Alberda, W, Albert, M, Andric, M, Angenete, E, Antoniou, A, Auer, R, Austin, KK, Aziz, O, Baker, RP, Bali, M, Baseckas, G, Bebington, B, Bednarski, BK, Beets, GL, Berg, PL, Beynon, J, Biondo, S, Boyle, K, Bordeianou, L, Bremers, AB, Brunner, M, Buchwald, P, Bui, A, Burgess, A, Burger, JWA, Burling, D, Burns, E, Campain, N, Carvalhal, S, Castro, L, Caycedo-Marulanda, A, Chan, KKL, Chew, GJH, Chong, PC, Christensen, HK, Clouston, H, Codd, M, Coffins, D, Colquhoun, AJ, Corr, A, Coscia, M, Coyne, PE, Creavin, B, Croner, RS, Damjanovic, L, Daniels, R, Davies, M, Davies, RJ, Delaney, CP, Denost, Q, Deutsch, C, Dietz, D, Domingo, S, Dozois, EJ, Duff, M, Eglinton, T, Enrique-Navascues, JM, Espin-Basany, E, Evans, MD, Fearnhead, NS, Flatmark, K, Fleming, F, Frizelle, FA, Gallego, MA, Garcia-Granero, E, Garcia-Sabrido, JL, Gentilini, L, George, ML, Ghouti, L, Giner, F, Ginther, N, Glynn, R, Golda, T, Griffiths, B, Harris, DA, Hagemans, JAW, Hanchanale, V, Harji, DP, Helewa, RM, Heriot, AG, Hochman, D, Hohenberger, W, Holm, T, Hompes, R, Jenkins, JT, Kaffenberger, S, Kandaswamy, GV, Kapur, S, Kanemitsu, Y, Kelley, SR, Keller, DS, Khan, MS, Kiran, RP, Kim, H, Kim, HJ, Koh, CE, Kok, NFM, Kokelaar, R, Kontovounisios, C, Kristensen, HO, Kroon, HM, Kusters, M, Lago, V, Larsen, SG, Larson, DW, Law, WL, Laurberg, S, Lee, PJ, Limbert, M, Lydrup, ML, Lyons, A, Lynch, AC, Mantyh, C, Mathis, KL, Margues, CFS, Martling, A, Meijerink, WJHJ, Merkel, S, Mehta, AM, McArthur, DR, McDermott, FD, McGrath, JS, Malde, S, Mimezami, A, Monson, JRT, Morton, JR, Mullaney, TG, Negoi, I, Neto, JWM, Nguyen, B, Nielsen, MB, Nieuwenhuijzen, GAP, Nilsson, PJ, O'Connell, PR, O'Dwyer, ST, Palmer, G, Pappou, E, Park, J, Patsouras, D, Pellino, G, Peterson, AC, Poggioli, G, Proud, D, Quinn, M, Quyn, A, Radwan, RW, van Ramshorst, GH, Rasheed, S, Rasmussen, PC, Regenbogen, SE, Renehan, A, Rocha, R, Rochester, M, Rohila, J, Rothbarth, J, Rottoli, M, Roxburgh, C, Rutten, HJT, Ryan, EJ, Safar, B, Sagar, PM, Sahai, A, Saklani, A, Sammour, T, Sayyed, R, Schizas, AMP, Schwarzkopf, E, Scripcariu, V, Selvasekar, C, Shaikh, I, Hellawell, G, Shida, D, Simpson, A, Smart, NJ, Smart, P, Smith, JJ, Solbakken, AM, Solomon, MJ, Sorensen, MM, Steele, SR, Steffens, D, Stitzenberg, K, Stocchi, L, Stylianides, NA, Sumrien, H, Sutton, PA, Swanking, T, Taylor, C, Tekkis, PP, Teras, J, Thurairaja, R, Toh, EL, Tsarkov, P, Tsukada, Y, Tsukamoto, S, Tuech, JJ, Turner, WH, Tuynman, JB, Vasquez-Jimenez, W, Verhoef, C, Vizzielli, G, Voogt, ELK, Uehara, K, Wakeman, C, Warner, S, Wasmuth, HH, Weber, K, Weiser, MR, Wheeler, JMD, Wild, J, Wilson, M, de Wilt, JHW, Wolthuis, A, Yano, H, Yip, B, Yip, J, Yoo, RN, van Zoggel, D, Winter, DC, Surgery, CCA - Cancer Treatment and quality of life, and Amsterdam Gastroenterology Endocrinology Metabolism
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,Colorectal cancer ,survival outcomes ,medicine.medical_treatment ,surgical outcome ,surgical outcomes ,Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14] ,03 medical and health sciences ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Interquartile range ,medicine ,Humans ,liver metastasi ,Rectal cancer ,Retrospective Studies ,Pelvic exenteration ,business.industry ,Rectal Neoplasms ,Mortality rate ,Liver Neoplasms ,Gastroenterology ,Postoperative complication ,Perioperative ,medicine.disease ,Surgery ,Pelvic Exenteration ,liver metastasis ,Treatment Outcome ,030220 oncology & carcinogenesis ,international collaboration ,Resection margin ,030211 gastroenterology & hepatology ,Hepatectomy ,Neoplasm Recurrence, Local ,business - Abstract
Aim: At presentation, 15–20% of patients with rectal cancer already have synchronous liver metastases. The aim of this study was to determine the surgical and survival outcomes in patients with advanced rectal cancer who underwent combined pelvic exenteration and liver (oligometastatic) resection. Method: Data from 20 international institutions that performed simultaneous pelvic exenteration and liver resection between 2007 and 2017 were accumulated. Primarily, we examined perioperative outcomes, morbidity and mortality. We also assessed the impact that margin status had on survival. Results: Of 128 patients, 72 (56.2%) were men with a median age of 60 years [interquartile range (IQR) 15 years]. The median size of the liver oligometastatic deposits was 2 cm (IQR 1.8 cm). The median duration of surgery was 406 min (IQR 240 min), with a median blood loss of 1090 ml (IQR 2010 ml). A negative resection margin (R0 resection) was achieved in 73.5% of pelvic exenterations and 66.4% of liver resections. The 30-day mortality rate was 1.6%, and 32% of patients had a major postoperative complication. The 5-year overall survival for patients in whom an R0 resection of both primary and metastatic disease was achieved was 54.6% compared with 20% for those with an R1/R2 resection (P = 0.006). Conclusion: Simultaneous pelvic exenteration and liver resection is feasible, with acceptable morbidity and mortality. Simultaneous resection should only be performed where an R0 resection of both pelvic and hepatic disease is anticipated.
- Published
- 2020
10. Intentional replantation to the endodontic-periodontal disease associated with misplacement of a rubber band-like foreign body: A case report
- Author
-
Miki Uehara, Yuko Seki, Satoko Kakino, Michiyo Miyashin, Tomoki Uehara, and Haruko Fujita
- Subjects
Intentional replantation ,business.product_category ,business.industry ,Free gingiva ,Dentistry ,030206 dentistry ,medicine.disease ,Lesion ,stomatognathic diseases ,03 medical and health sciences ,0302 clinical medicine ,Periodontal disease ,Pediatrics, Perinatology and Child Health ,medicine ,Rubber band ,Oral examination ,Dentistry (miscellaneous) ,Foreign body ,medicine.symptom ,business ,030217 neurology & neurosurgery ,Pulp necrosis - Abstract
The authors report a case of severe periodontal destruction and subsequent pulp necrosis. Intentional replantation was performed to treat and investigate of the cause of this idiopathic, rapidly progressive, endodontic-periodontal lesion. A rubber band-like foreign body was incidentally discovered in the periodontal tissue. Although dislocation of a foreign body during dental treatment is unusual, it may happen occasionally. Careful oral examination is recommended, and a fissure-like deep crease in the free gingiva may be helpful in diagnosing misplacement of a foreign body in the periodontal tissue.
- Published
- 2021
11. How Successful Is Parenteral Oxycodone for Relieving Terminal Cancer Dyspnea Compared With Morphine? A Multicenter Prospective Observational Study
- Author
-
Masanori Mori, Takashi Kawaguchi, Kengo Imai, Naosuke Yokomichi, Takashi Yamaguchi, Kozue Suzuki, Ryo Matsunuma, Hiroaki Watanabe, Isseki Maeda, Yuko Uehara, Tatsuya Morita, Satoshi Inoue, Hiroaki Tsukuura, Toshihiro Yamauchi, Akemi Shirado Naito, Yu Uneno, Akira Yoshioka, Shuji Hiramoto, Ayako Kikuchi, Tetsuo Hori, Yosuke Matsuda, Hiroyuki Kohara, Hiromi Fanaki, Keiko Tanaka, Tina Kamei, Yukari Azuma, Koji Amano, Teruaki Uno, Jiro Miyamoto, Hirofumi Katayama, Hideyuki Kashiwagi, Eri Matsumoto, Kiyofumi Oya, Takeya Yamaguchi, Tomonao Okamura, Hoshu Hashimoto, Shunsuke Kosugi, Nao Ikuta, Yaichiro Matsumoto, Takashi Ohmori, Takehiro Nakai, Takashi Ikee, Yuto Unoki, Kazuki Kitade, Shu Koito, Nanao Ishibashi, Masaya Ehara, Kosuke Kuwahara, Shohei Ueno, Shunsuke Nakashima, Yuta Ishiyama, Akihiro Sakashita, Hana Takatsu, Satoko Ito, Toru Terabayashi, Jun Nakagawa, Tetsuya Yamagiwa, Akira Inoue, Takuhiro Yamaguchi, Mitsunori Miyashita, Saran Yoshida, Yusuke Hiratsuka, Keita Tagami, Takuya Odagiri, Tetsuya Ito, Masayuki Ikenaga, Keiji Shimizu, Akira Hayakawa, Rena Kamura, Takeru Okoshi, Tomohiro Nishi, Kazuhiro Kosugi, Yasuhiro Shibata, Takayuki Hisanaga, Takahiro Higashibata, Ritsuko Yabuki, Shingo Hagiwara, Miho Shimokawa, Satoshi Miyake, Junko Nozato, Hiroto Ishiki, Tetsuji Iriyama, Keisuke Kaneishi, Mika Baba, Tomofumi Miura, Yoshihisa Matsumoto, Ayumi Okizaki, Yuki Sumazaki Watanabe, Yuko uehara, Eriko Satomi, Kaoru Nishijima, Junichi Shimoinaba, Ryoichi Nakahori, Takeshi Hirohashi, Jun Hamano, Natsuki Kawashima, Megumi Uchida, Ko Sato, Yoichi Matsuda, Yutaka Hatano, Satoru Tsuneto, Sayaka Maeda, Yoshiyuki Kizawa, and Hiroyuki Otani
- Subjects
Lung Neoplasms ,Palliative care ,Subgroup analysis ,Context (language use) ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,medicine ,Humans ,030212 general & internal medicine ,Lung cancer ,General Nursing ,Aged ,Morphine ,business.industry ,Cancer ,medicine.disease ,respiratory tract diseases ,Analgesics, Opioid ,Dyspnea ,Anesthesiology and Pain Medicine ,030220 oncology & carcinogenesis ,Anesthesia ,Neurology (clinical) ,business ,Oxycodone ,medicine.drug - Abstract
Parenteral morphine is widely used for dyspnea of imminently dying cancer patients (terminal dyspnea). However, the efficacy of other opioids such as oxycodone remains largely unknown.To explore the efficacy of parenteral oxycodone vs. morphine by continuous infusion over 24 hours in cancer patients with terminal dyspnea.This was a pre-planned subgroup analysis of a multicenter prospective observational study. Inclusion criteria were advanced cancer patients admitted to palliative care units, Eastern Cooperative Oncology Group performance status = 3-4, and a dyspnea intensity ≥2 on the Integrated Palliative care Outcome Scale (IPOS) for which oxycodone or morphine was initiated by continuous infusion. We measured dyspnea IPOS scores over 24 hours.We analyzed 164 patients who received oxycodone (n = 26) and morphine (n = 138) for dyspnea (median survival = 5 days). The mean age was 70 years, 58 patients (35%) had lung cancer, and 97 (59%) had lung metastases. Complete case analysis revealed that mean dyspnea IPOS scores decreased from 3.0 (standard deviation = 0.7) to 1.5 (0.7) in the oxycodone group (difference in means = 1.5; P 0.001), and from 2.9 (0.7) to 1.6 (1.0) in the morphine group (difference in means = 1.3; P 0.001). No significant between-group differences existed in the IPOS scores at 24 hours (P = 0.753). Adverse events were seen in no and 5 patients in the oxycodone and morphine groups, respectively.Parenteral oxycodone may be equally effective and safe as morphine in the treatment of terminal dyspnea in cancer patients. Future randomized controlled trials should confirm the efficacy and safety of opioids other than morphine for terminal dyspnea.
- Published
- 2021
12. Taurodeoxycholic acid and valine reverse obesity-associated augmented alloimmune responses and prolong allograft survival
- Author
-
Hirofumi Uehara, Jasper Iske, Abdallah Elkhal, Tomohisa Matsunaga, Yang Liu, David L. Perkins, Yeqi Nian, Hao Zhou, Koichiro Minami, Stefan G. Tullius, Markus Quante, Haruhito Azuma, Ryochi Maenosono, and Maria-Luisa Alegre
- Subjects
Graft Rejection ,medicine.medical_specialty ,T cell ,Inflammation ,Pharmacology ,Organ transplantation ,Mice ,chemistry.chemical_compound ,Valine ,medicine ,Animals ,Humans ,Immunology and Allergy ,Pharmacology (medical) ,Mice, Inbred BALB C ,Taurodeoxycholic Acid ,Transplantation ,business.industry ,Graft Survival ,Alloimmunity ,Allografts ,G protein-coupled bile acid receptor ,Obesity, Morbid ,Mice, Inbred C57BL ,medicine.anatomical_structure ,chemistry ,Heart Transplantation ,Taurodeoxycholic acid ,medicine.symptom ,business - Abstract
Obesity initiates a chronic inflammatory network linked to perioperative complications and increased acute rejection rates in organ transplantation. Bariatric surgery is the most effective treatment of obesity recommended for morbidly obese transplant recipients. Here, we delineated the effects of obesity and bariatric surgery on alloimmunity and transplant outcomes in diet-induced obese (DIO) mice. Allograft survival was significantly shorter in DIO-mice. When performing sleeve gastrectomies (SGx) prior to transplantation, we found attenuated T cell-derived alloimmune responses resulting in prolonged allograft survival. Administering taurodeoxycholic acid (TDCA) and valine, metabolites depleted in DIO-mice and restored through SGx, prolonged graft survival in DIO-mice comparable with SGx an dampened Th1 and Th17 alloimmune responses while Treg frequencies and CD4+ T cell-derived IL-10 production were augmented. Moreover, in recipient animals treated with TDCA/valine, levels of donor-specific antibodies had been reduced. Mechanistically, TDCA/valine restrained inflammatory M1-macrophage polarization through TGR5 that compromised cAMP signaling and inhibited macrophage-derived T cell activation. Consistently, administering a TGR5 agonist to DIO-mice prolonged allograft survival. Overall, we provide novel insights into obesity-induced inflammation and its impact on alloimmunity. Furthermore, we introduce TDCA/valine as a noninvasive alternative treatment for obese transplant patients.
- Published
- 2022
13. Frequency of Change in Assessment from Bony Union to Nonunion after Lumbar Interbody Fusion: A Multicenter Study
- Author
-
Hiroki Oba, Tetsuro Ohba, Zentaro Yamagata, Terue Hatakenaka, Yukihiro Isogai, Shota Ikegami, Hirotaka Haro, Toshiyuki Ojima, Ryo Munakata, Shugo Kuraishi, Yosuke Shibata, Masashi Uehara, Jun Takahashi, Takashi Takizawa, Yukihiro Matsuyama, and Tomohiko Hasegawa
- Subjects
medicine.medical_specialty ,delayed fusion ,RD1-811 ,business.industry ,Bony union ,Nonunion ,bony union ,posterior lumbar interbody fusion ,weekly teriparatide ,medicine.disease ,Surgery ,Multicenter study ,Lumbar interbody fusion ,transforaminal lumbar interbody fusion ,Medicine ,Orthopedics and Sports Medicine ,Neurology (clinical) ,business ,bone resorption - Abstract
Introduction: Assessments of early postoperative bony union after posterior lumbar interbody fusion via computed tomography (CT) have revealed cases in which interbody fixation by bony union resulted in nonfusion due to bone absorption. The apparent bone union state reverted to a nonunion state several months later, exhibiting a so-called “fake union” phenomenon. Additionally, few reports have evaluated the effect of teriparatide on bony union. The present study aimed to evaluate the frequency of change in assessment from fusion to nonfusion in the postoperative follow-up of lumbar interbody fusion, compare the late postoperative bony union rates in groups with or without early postoperative fusion, and examine the effect of postoperative teriparatide in those groups. Methods: Sixty-nine subjects enrolled from multiple hospitals were prospectively evaluated following single-level lumbar interbody fusion. The patients were randomly allocated into treatment with or without weekly postoperative teriparatide. The subjects were then classified as having bony union or nonfusion at 2 months postoperatively, and fusion rates at 6 months were compared. For the evaluation of bony union, blinded radiological examinations were performed via CT. Additional comparisons were made according to teriparatide use. Results: The rate of nonunion at 6 months postoperatively in patients with fusion at 2 months postoperatively was 27.8%. Among subjects with bony union at 2 months postoperatively, the fusion rate at 6 months in those who received teriparatide was 93.3% (p=0.027) versus 57.1% in those who did not. Conclusions: The rate of nonunion at 6 months postoperatively in patients exhibiting union at 2 months after surgery was 27.8%. Postoperative weekly teriparatide treatment significantly reduced the rate of fake union.
- Published
- 2022
14. Nationwide surveillance of the antimicrobial susceptibility of Chlamydia trachomatis from male urethritis in Japan: Comparison with the first surveillance report
- Author
-
Takahiro Maruyama, Shinya Uehara, Koichi Hatano, Junko Sato, Ryoichi Hamasuna, Satoshi Uno, Hiroshi Kiyota, Kiyohito Ishikawa, Shingo Yamamoto, Yoshiki Hiyama, Motoshi Kawahara, Kanao Kobayashi, Keijiro Kiyoshima, Jun Miyazaki, Masaru Matumura, Toru Sumii, Hideo Hirayama, Kazushi Tanaka, Kazumasa Matsumoto, Kenji Hayashi, Shuichi Kawai, Naoya Masumori, Koichi Monden, Shin Ito, Kenji Ito, Yoshikazu Togo, Katsumi Shigemura, Masanobu Izumitani, Masayasu Ito, Hiroshi Yotsuyanagi, Takahide Hosobe, Yutaka Shiono, Kazuo Takayama, Hideaki Hanaki, Mitsuru Yasuda, Mutsumasa Yoh, Hiroshi Hayami, Hideari Ihara, Teruhiko Yokoyama, Hirofumi Nishimura, Tetsuya Matsumoto, Hiroki Yamada, Motonori Kano, Kazuhiro Tateda, Shin Egawa, Masahiro Matsumoto, Hitoshi Kadena, Shinichi Kaji, Hiroyuki Kitano, Ryuji Fujita, Takanori Tojo, Koichiro Wada, and Satoshi Takahashi
- Subjects
Male ,Microbiology (medical) ,Sitafloxacin ,medicine.medical_specialty ,Solithromycin ,Erythromycin ,Chlamydia trachomatis ,Microbial Sensitivity Tests ,Azithromycin ,medicine.disease_cause ,Tosufloxacin ,Japan ,Levofloxacin ,Internal medicine ,Drug Resistance, Bacterial ,medicine ,Humans ,Pharmacology (medical) ,Urethritis ,business.industry ,medicine.disease ,Anti-Bacterial Agents ,Infectious Diseases ,business ,medicine.drug - Abstract
The Urogenital Sub-committee and the Surveillance Committee of the Japanese Society of Chemotherapy, The Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology conducted the second nationwide surveillance of the antimicrobial susceptibility of Chlamydia trachomatis. In this second surveillance study, clinical urethral discharge specimens were collected from patients with urethritis in 26 hospitals and clinics from May 2016 to July 2017. Based on serial cultures, the minimum inhibitory concentration (MIC) could be determined for 41 isolates; the MICs (MIC90) of ciprofloxacin, levofloxacin, tosufloxacin, sitafloxacin, doxycycline, minocycline, erythromycin, clarithromycin, azithromycin and solithromycin were 2 μg/ml (2 μg/ml), 1 μg/ml (0.5 μg/ml), 0.25 μg/ml (0.25 μg/ml), 0.125 μg/ml (0.063 μg/ml), 0.125 μg/ml (0.125 μg/ml), 0.25 μg/ml (0.25 μg/ml), 0.031 μg/ml (0.031 μg/ml), 0.25 μg/ml (0.125 μg/ml), and 0.016 μg/ml (0.008 μg/ml), respectively. In summary, this surveillance project did not identify any strains resistant to fluoroquinolone, tetracycline, or macrolide agents in Japan. In addition, the MIC of solithromycin was favorable and lower than that of other antimicrobial agents. However, the MIC of azithromycin had a slightly higher value than that reported in the first surveillance report, though this might be within the acceptable margin of error. Therefore, the susceptibility of azithromycin, especially, should be monitored henceforth.
- Published
- 2022
15. Feature extraction from I/Q signals for ZigBee devices identification
- Author
-
Yuichi Miyaji, Hideyuki Uehara, Ryota Shinoda, and Ibuki Yoshitani
- Subjects
Identification (information) ,Computer science ,business.industry ,Feature extraction ,Pattern recognition ,Artificial intelligence ,business - Published
- 2021
16. A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab
- Author
-
Kensuke Kondo, Yohei Yabuki, Hiroshi Nokihara, Atsushi Mitsuhashi, Hiroto Yoneda, Akane Abe, Masahiro Sako, Yasuhiko Nishioka, Kenji Otsuka, Ryohiko Ozaki, Hirokazu Ogino, and Hisanori Uehara
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,medicine.medical_specialty ,pulmonary pleomorphic carcinoma ,medicine.medical_treatment ,Case Report ,Pembrolizumab ,Case Reports ,Pleomorphic carcinoma ,Refractory ,Internal medicine ,medicine ,Interstitial pneumonia ,Adverse effect ,Lung cancer ,RC254-282 ,Pneumonitis ,interstitial pneumonia ,Chemotherapy ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,General Medicine ,medicine.disease ,pembrolizumab ,business - Abstract
Pulmonary pleomorphic carcinoma is often refractory to chemotherapy and follows an aggressive clinical course. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced lung cancer, and a few cases with pleomorphic carcinoma have been reported to show tumor shrinkage after therapy with ICIs. When treating patients with ICIs, patient selection is essential, and monitoring and management of immune‐related adverse events, including pneumonitis, are needed. We herein report a case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia treated with pembrolizumab, antiprogrammed cell death 1 antibody. Our report highlights important considerations necessary when treating advanced pleomorphic carcinoma patients complicated with interstitial pneumonia. We also review the literature regarding the use of ICIs in such patients.
- Published
- 2021
17. High-dose melphalan-based chemotherapy and autologous stem-cell transplantation for high-risk osteosarcoma in children: A single-institute experience and review of the literature
- Author
-
Shinobu Kiyuna, Jiro Miyamoto, Taichi Uehara, Hideki Sakiyama, Takeshi Higa, Takeshi Yagi, Koichi Nakanishi, Takehiro Matsuda, Tokiko Oshiro, Satoru Hamada, and Nobuyuki Hyakuna
- Subjects
Oncology ,Melphalan ,medicine.medical_specialty ,medicine.medical_treatment ,ThioTEPA ,Pediatrics ,RJ1-570 ,Autologous stem-cell transplantation ,Internal medicine ,medicine ,Mucositis ,High-dose chemotherapy ,neoplasms ,Etoposide ,Chemotherapy ,Osteosarcoma ,Ifosfamide ,business.industry ,Hematology ,medicine.disease ,Transplantation ,Pediatrics, Perinatology and Child Health ,business ,medicine.drug - Abstract
Background The prognosis of high-risk osteosarcoma, defined by the presence of chemo-resistance, metastatic disease at diagnosis, and relapse, remains poor. The efficacy of high-dose chemotherapy (HDC) and autologous stem-cell transplantation (ASCT) for high-risk osteosarcoma is still unclear. Methods We retrospectively reviewed pediatric patients with high-risk osteosarcoma who underwent HDC and ASCT at our institution between 2002 and 2018 and performed a review of the literature regarding the efficacy of HDC and ASCT for high-risk osteosarcoma. Results Six patients with high-risk osteosarcoma underwent high-dose melphalan (180 mg/m2)-based chemotherapy followed by ASCT. Two patients received HDC consisting of ifosfamide and melphalan. Three patients received HDC consisting of etoposide, carboplatin, and melphalan. One patient underwent tandem HDC consisting of thiotepa and etoposide followed by melphalan, thiotepa, and etoposide. Non-hematological toxicities presented mainly as mucositis and diarrhea. Two patients developed grade 3 mucositis. No life-threatening toxicities were observed in any of the six patients. One patient with disease progression before HDC died of multiple metastases, while five patients, with no evidence of disease in the peri-transplant periods, were alive at the time of publication; there was no disease recurrence at a median follow-up period of 144 months (range, 24–215 months). Our review of the literature supports the use of HDC with a higher dose of melphalan (180–280 mg/m2) for high-risk osteosarcoma. Conclusions Melphalan-based HDC and ASCT can be a promising treatment for high-risk osteosarcoma. Additionally, surgical removal of macroscopic residual lesions may be essential in peri-transplant periods.
- Published
- 2021
18. The prevalence of artificially administered nutrition and hydration in different age groups among patients with advanced cancer admitted to palliative care units
- Author
-
Jiro Miyamoto, Hiroto Ishiki, Kaoru Nishijima, Masayuki Ikenaga, Kazuki Kitade, Natsuki Kawashima, Keiji Shimizu, Akira Inoue, Takeshi Hirohashi, Shuji Hiramoto, Hoshu Hashimoto, Yoichi Matsuda, Junko Nozato, Keisuke Kaneishi, Kosuke Kuwahara, Takashi Ohmori, Junichi Shimoinaba, Kengo Imai, Takehiro Nakai, Satoshi Inoue, Yosuke Matsuda, Toshihiro Yamauchi, Ritsuko Yabuki, Takahiro Higashibata, Rena Kamura, Satoru Tsuneto, Tetsuya Ito, Masaya Ehara, Eri Matsumoto, Ryo Matsunuma, Yoshihisa Matsumoto, Keiko Tanaka, Masanori Mori, Yuko Uehara, Toru Terabayashi, Yutaka Hatano, Yuki Sumazaki Watanabe, Teruaki Uno, Hirofumi Katayama, Yuto Unoki, Takayuki Hisanaga, Tomohiro Nishi, Akemi Shirado Naito, Hiroaki Tsukuura, Ayumi Okizaki, Koji Amano, Shingo Hagiwara, Tetsuo Hori, Tomonao Okamura, Satoko Ito, Yusuke Hiratsuka, Ko Sato, Takeya Yamaguchi, Tatsuya Morita, Hiromi Funaki, Yukari Azuma, Akihiro Sakashita, Hana Takatsu, Takuhiro Yamaguchi, Satoshi Miyake, Sayaka Maeda, Hideyuki Kashiwagi, Ryoichi Nakahori, Jun Nakagawa, Takashi Yamaguchi, Keita Tagami, Nanao Ishibashi, Yaichiro Matsumoto, Naosuke Yokomichi, Kiyofumi Oya, Shu Koito, Miho Shimokawa, Eriko Satomi, Kazuhiro Kosugi, Megumi Uchida, Yasuhiro Shibata, Tina Kamei, Jun Hamano, Akira Hayakawa, Takashi Ikee, Tetsuji Iriyama, Takuya Odagiri, Yu Uneno, Shunsuke Nakashima, Mitsunori Miyashita, Nao Ikuta, Takashi Kawaguchi, Yoshiyuki Kizawa, Mika Baba, Saran Yoshida, Tetsuya Yamagiwa, Isseki Maeda, Akira Yoshioka, Shohei Ueno, Yuta Ishiyama, Hiroyuki Kohara, Shunsuke Oyamada, Ayako Kikuchi, Hiroyuki Otani, Kozue Suzuki, Hiroaki Watanabe, Shunsuke Kosugi, Takeru Okoshi, and Tomofumi Miura
- Subjects
medicine.medical_specialty ,Nutrition and Dietetics ,Palliative care ,Calorie ,Younger age ,business.industry ,Parenteral hydration ,Nutrition. Foods and food supply ,Endocrinology, Diabetes and Metabolism ,Parenteral nutrition ,Advanced cancer ,Artificially administered nutrition ,Age groups ,Internal medicine ,medicine ,Parenteral route ,TX341-641 ,Enteral tube feeding ,Prospective cohort study ,business ,Artificially administered hydration - Abstract
Summary: Background & Aims: The prevalence of artificially administered nutrition and hydration (AANH) in different age groups among patients with advanced cancer remains unknown. The present study investigated the current utilization of AANH according to age groups in palliative care units. Methods: This was a secondary analysis of a prospective cohort study. We obtained information on primary nutritional administration routes during the first week of admission and data on the averaged calorie sufficiency rate or total calorie intake on the 7th day of admission. Patients were divided into five age groups (18–39, 40–59, 60–74, 75–89, and 90- years). Among patients receiving AANH, the proportions of higher-calorie AANH were compared between the five age groups. Results: A total of 1453 patients were included. The proportion of patients categorized as receiving nutrition and hydration via the parenteral route was the highest in the 18–39 and 40–59 groups (52.4 and 41.1%, respectively). Among patients receiving AANH (n = 534), the proportions of patients categorized into the
- Published
- 2021
19. Reflection of the Ictal Electrocorticographic Discharges Confined to the Medial Temporal Lobe to the Scalp-Recorded Electroencephalogram
- Author
-
Nobutaka Mukae, Taira Uehara, Ayumi Sakata, Takato Morioka, Hiroshi Shigeto, Koji Yoshimoto, and Takafumi Shimogawa
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,General Medicine ,Electroencephalography ,Audiology ,medicine.disease ,Scalp eeg ,nervous system diseases ,Temporal lobe ,Epilepsy ,Burst suppression ,medicine.anatomical_structure ,nervous system ,Neurology ,Scalp ,medicine ,Ictal ,Neurology (clinical) ,business ,neoplasms ,Electrocorticography - Abstract
Objective: Previous reports on the simultaneous recording of electroencephalography (EEG) and electrocorticography (ECoG) have demonstrated that, in patients with temporal lobe epilepsy (TLE), ictal ECoG discharges with an amplitude as high as 1000 μV originating from the medial temporal lobe could not be recorded on EEG. In contrast, ictal EEG discharges were recorded after ictal ECoG discharges propagated to the lateral temporal lobe. Here, we report a case of TLE in which the ictal EEG discharges, corresponding to ictal ECoG discharges confined to the medial temporal lobe, were recorded. Case report: In the present case, ictal EEG discharges were hardly recognized when the amplitude of the ECoG discharges was less than 1500 μV. During the evolution and burst suppression phase, corresponding to highly synchronized ECoG discharges with amplitudes greater than 1500 to 2000 μV, rhythmic negative waves with the same frequency were clearly recorded both on the lateral temporal lobe and scalp. The amplitude of the lateral temporal ECoG was approximately one-tenth of that of the medial temporal ECoG. The amplitude of the scalp EEG was approximately one-tenth of that of the lateral temporal ECoG. Conclusions: Highly synchronized ictal ECoG discharges with high amplitude of greater than 1500 to 2000 μV in the medial temporal lobe could be recorded on the scalp as ictal EEG discharges via volume conduction.
- Published
- 2021
20. Concordance of the histological diagnosis of type 1 autoimmune pancreatitis and its distinction from pancreatic ductal adenocarcinoma with endoscopic ultrasound-guided fine needle biopsy specimens: an interobserver agreement study
- Author
-
Terumi Kamisawa, Shinichi Aishima, Mamiko Nagase, Takayoshi Nishino, Masashi Miyaoka, Yuki Fukumura, Satomi Kasashima, Teruko Tomono, Itaru Naitoh, Nobuyuki Ohike, Takuma Tajiri, Motohiro Kojima, Atsushi Kanno, Kenji Notohara, Shigeyuki Kawa, Hiroshi Yamaguchi, Kyoko Shimizu, Kensuke Kubota, Shota Kobayashi, Shinsuke Oda, Kenichi Hirabayashi, Yasuhiro Kuraishi, Toru Furukawa, Noriyoshi Fukushima, Yoshiki Naito, Kazuichi Okazaki, Tsukasa Ikeura, Atsuhiro Kawashima, Junichi Sakagami, Sho Tsuyama, Junko Nakashima, Eisuke Iwasaki, Syunsuke Watanabe, Takeshi Uehara, Masamichi Nakayama, Hideyo Fujiwara, Masayo Motoya, Tomoko Mitsuhashi, Emi Ibuki, and Daiki Taniyama
- Subjects
Endoscopic ultrasound ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Concordance ,Cell Biology ,General Medicine ,medicine.disease ,Pathology and Forensic Medicine ,Lesion ,Fibrosis ,Metaplasia ,Biopsy ,medicine ,Radiology ,Medical diagnosis ,medicine.symptom ,business ,Molecular Biology ,Autoimmune pancreatitis - Abstract
The histological diagnosis of type 1 autoimmune pancreatitis (AIP) based on the findings obtained by an endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) is feasible, but the diagnostic consistency of this method has not been confirmed. We determined the interobserver agreement among 20 pathologists regarding the diagnosis of type 1 AIP, including the distinction from pancreatic ductal adenocarcinoma (PDAC) using large tissue samples obtained by EUS-FNB. After guidance for diagnosing AIP with biopsy tissues was provided, a round 2 was performed. The median sensitivity and specificity for diagnosing PDAC vs. non-neoplastic diseases were 95.2% and 100%, respectively. In groups of specialists (n = 7) and the generalists (n = 13), Fleiss’ к-values increased from 0.886 to 0.958 and from 0.750 to 0.816 in round 2. The concordance was fair or moderate for obliterative phlebitis and storiform fibrosis but slight for ductal lesion of type 1 AIP. Discordant results were due to ambiguous findings and biopsy tissue limitations. Among the specialists, the ratio of cases with perfect agreement regarding the presence of storiform fibrosis increased in round 2, but agreement regarding obliterative phlebitis or ductal lesions was not improved. Although the histological definite diagnosis of type 1 AIP was achieved by most observers in > 60% of the cases, the confidence levels varied. Because some ambiguities exist, the histological diagnostic levels based on the diagnostic criteria of type 1 AIP should not be taken for granted. Guidance is effective for improving accurate PDAC diagnoses (notably by recognizing acinar-ductal metaplasia) and for evaluating storiform fibrosis.
- Published
- 2021
21. Listeria monocytogenes Bacteremia During Isatuximab Therapy in a Patient with Multiple Myeloma
- Author
-
Yujiro Uchida, Yasufumi Uehara, Yuju Ohno, Yoriko Sato, Hiroshi Imanaga, Yasuhiro Sugio, Takanori Ohta, Toshiyuki Ueno, and Megumi Nakazawa
- Subjects
Isatuximab ,business.industry ,General Medicine ,030204 cardiovascular system & hematology ,Pneumocystis pneumonia ,medicine.disease ,medicine.disease_cause ,Drug eruption ,03 medical and health sciences ,0302 clinical medicine ,Listeria monocytogenes ,Ampicillin ,Bacteremia ,Immunology ,Internal Medicine ,medicine ,030211 gastroenterology & hepatology ,business ,Atovaquone ,Multiple myeloma ,medicine.drug - Abstract
An elderly patient with multiple myeloma (MM) was being treated with several regimens and developed a severe drug eruption, necessitating the use of atovaquone instead of trimethoprim-sulfamethoxazole for pneumocystis pneumonia (PCP) prophylaxis. For progressive MM, treatment with isatuximab, an anti-CD38 monoclonal antibody, was started. During the treatment, he developed Listeria monocytogenes bacteremia and recovered quickly with ampicillin administration. CD38 is closely related to the innate immune response against L. monocytogenes, and isatuximab may increase the risk of infection. Therefore, trimethoprim-sulfamethoxazole may be useful in the prevention of not only PCP but also L. monocytogenes infection.
- Published
- 2021
22. Indications for conversion hepatectomy for initially unresectable colorectal cancer with liver metastasis
- Author
-
Masato Komoda, Yoshiaki Fujimoto, Keiichi Shiokawa, Yuichiro Nakashima, Manabu Yamamoto, Masahiko Sugiyama, Yasushi Toh, Yohei Mano, Masaru Morita, Keishi Sugimachi, Yuki Shin, and Hideo Uehara
- Subjects
Chemotherapy ,medicine.medical_specialty ,Colorectal cancer ,business.industry ,medicine.medical_treatment ,Liver Neoplasms ,Patient characteristics ,General Medicine ,Odds ratio ,medicine.disease ,Gastroenterology ,Metastasis ,Survival Rate ,Surgical oncology ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Extrahepatic metastasis ,Hepatectomy ,Humans ,Surgery ,Colorectal Neoplasms ,business ,Retrospective Studies - Abstract
Selected patients with initially unresectable colorectal cancer (CRC) and liver metastases undergo conversion surgery after appropriate chemotherapy. The prognosis of these patients is good, with some even cured of the disease. This retrospective, single-institution study analyzes the clinical importance of patient characteristics on the outcomes of conversion hepatectomy. We evaluated 229 consecutive patients with initially unresectable CRC and liver metastasis, who underwent systemic chemotherapy. The patients were assigned to groups depending on conversion hepatectomy. Conversion hepatectomy was performed in 30 patients (13.1%). The proportion of patients with extrahepatic metastasis was significantly lower in the conversion group than in the unresectable group (30.0 vs. 66.8%; P
- Published
- 2021
23. Superiority of clinical American Joint Committee on Cancer T classification for perihilar cholangiocarcinoma
- Author
-
Nobuyuki Watanabe, Shunsuke Onoe, Tomoki Ebata, Keitaro Matsuo, Tsuyoshi Igami, Mihoko Yamada, Takashi Mizuno, Kay Uehara, Yukihiro Yokoyama, and Junpei Yamaguchi
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,medicine.medical_treatment ,Area under the curve ,Cancer ,Tumor Staging ,Prognosis ,medicine.disease ,United States ,Resection ,Cholangiocarcinoma ,Bile Duct Neoplasms ,Survival probability ,Laparotomy ,medicine ,Humans ,Surgery ,Radiology ,Perihilar Cholangiocarcinoma ,business ,Klatskin Tumor ,Neoplasm Staging ,T classification - Abstract
BACKGROUND Clinical tumor staging is essential information for making a therapeutic decision in cancer. This study aimed to identify the optimal tumor classification system for predicting resectability and survival probability in perihilar cholangiocarcinoma. METHODS Patients who were treated for perihilar cholangiocarcinoma between 2009 and 2018 were enrolled. Local tumor extension was staged radiologically according to a diameter-based classification system in addition to the AJCC, Blumgart, and Bismuth systems. Survival and resectability were compared between T subgroups, and the discriminability of the four systems was assessed with Harrell's concordance index (C-index). RESULTS Among 702 study patients, 559 (80.0%) underwent laparotomy, 489 (70.0%) of whom underwent resection. The resectability significantly decreased for more advanced tumors in all systems (P
- Published
- 2021
24. AKT controls protein synthesis and oxidative metabolism via combined mTORC1 and FOXO1 signalling to govern muscle physiology
- Author
-
Kahealani Uehara, Paul M. Titchenell, Paul A. Roberson, Nicole Rivera-Fuentes, Tejvir S. Khurana, Michael D. Neinast, Zoltan Arany, Scot R. Kimball, Jaimarie Sostre-Colón, Matthew Gavin, Natasha Jaiswal, and Emanuele Loro
- Subjects
medicine.medical_specialty ,Disuse‐induced muscle wasting ,AKT1 ,FOXO1 ,Diseases of the musculoskeletal system ,mTORC1 ,Mechanistic Target of Rapamycin Complex 1 ,Cachexia ,Muscle hypertrophy ,Mice ,Physiology (medical) ,Internal medicine ,medicine ,Animals ,Orthopedics and Sports Medicine ,Muscle, Skeletal ,Protein kinase B ,Insulin action ,Forkhead Box Protein O1 ,business.industry ,QM1-695 ,Skeletal muscle ,medicine.disease ,Fibre specification ,Oxidative Stress ,medicine.anatomical_structure ,Endocrinology ,RC925-935 ,Sarcopenia ,Human anatomy ,AKT signalling ,business ,Proto-Oncogene Proteins c-akt ,Signal Transduction - Abstract
Background Skeletomuscular diseases result in significant muscle loss and decreased performance, paralleled by a loss in mitochondrial and oxidative capacity. Insulin and insulin‐like growth factor‐1 (IGF‐1) are two potent anabolic hormones that activate a host of signalling intermediates including the serine/threonine kinase AKT to influence skeletal muscle physiology. Defective AKT signalling is associated with muscle pathology, including cachexia, sarcopenia, and disuse; however, the mechanistic underpinnings remain unresolved. Methods To elucidate the role of AKT signalling in muscle mass and physiology, we generated both congenital and inducible mouse models of skeletal muscle‐specific AKT deficiency. To understand the downstream mechanisms mediating AKT's effects on muscle biology, we generated mice lacking AKT1/2 and FOXO1 (M‐AKTFOXO1TKO and M‐indAKTFOXO1TKO) to inhibit downstream FOXO1 signalling, AKT1/2 and TSC1 (M‐AKTTSCTKO and M‐indAKTTSCTKO) to activate mTORC1, and AKT1/2, FOXO1, and TSC1 (M‐QKO and M‐indQKO) to simultaneously activate mTORC1 and inhibit FOXO1 in AKT‐deficient skeletal muscle. Muscle proteostasis and physiology were assessed using multiple assays including metabolic labelling, mitochondrial function, fibre typing, ex vivo physiology, and exercise performance. Results Here, we show that genetic ablation of skeletal muscle AKT signalling resulted in decreased muscle mass and a loss of oxidative metabolism and muscle performance. Specifically, deletion of muscle AKT activity during development or in adult mice resulted in a significant reduction in muscle growth by 30–40% (P
- Published
- 2021
25. Anti‐polymyositis/Scl antibody‐positive overlap syndrome of diffuse cutaneous systemic sclerosis, dermatomyositis, systemic lupus erythematosus, and antiphospholipid syndrome
- Author
-
Sayaka Toki, Sei-ichiro Motegi, Masahito Yasuda, Akihiko Uchiyama, Yukie Endo, Mayu Nishio, Yoshinao Muro, Shintaro Saito, Akihito Uehara, and Osamu Ishikawa
- Subjects
Adult ,Male ,myalgia ,medicine.medical_specialty ,Dermatology ,Polymyositis ,Dermatomyositis ,Leukoencephalopathy ,Pericarditis ,Antiphospholipid syndrome ,medicine ,Humans ,Lupus Erythematosus, Systemic ,Autoantibodies ,Scleroderma, Systemic ,business.industry ,Interstitial lung disease ,Overlap syndrome ,General Medicine ,Antiphospholipid Syndrome ,medicine.disease ,Scleroderma, Diffuse ,medicine.symptom ,business - Abstract
A 37-year-old Japanese man with a 3-year history of diffuse cutaneous systemic sclerosis was admitted to our hospital with high fever, arthralgia, myalgia, and muscle weakness. A physical examination revealed facial erythema, Gottron's sign, and mechanic's hands in addition to skin sclerosis. Laboratory data revealed significantly elevated levels of creatine kinase and decreased complement. Anti-RNP, anti-Smith, anti-DNA, anti-β2 -glycoprotein 1, anti-polymyositis (PM)/Scl75, and anti-PM/Scl100 antibodies were detected. He also had urinary protein, interstitial lung disease, pericarditis, multifocal cerebral infarctions, and leukoencephalopathy. Thus, a diagnosis of overlap syndrome of diffuse cutaneous systemic sclerosis, dermatomyositis, and systemic lupus erythematosus with antiphospholipid syndrome was made. Because of the intractable course, he was treated with multiple immunosuppressive and immunomodulatory drugs, including three rounds of 1000 mg methylprednisolone pulse therapy. This is the first case report of anti-PM/Scl antibody-positive overlap syndrome of three major connective tissue diseases.
- Published
- 2021
26. Construction of a computational mechanical model of bronchi for practical simulation of the optimal positive intrathoracic pressure conditions during general thoracic surgery
- Author
-
Suguru Shirai, Hiroshi Kondo, Y. Sakao, Masafumi Kawamura, Tadashi Tanuma, Yuichi Saito, Yoshikane Yamauchi, Hirofumi Uehara, Atsushi Yasuda, and T. Yokobori
- Subjects
Insufflation ,medicine.medical_specialty ,General thoracic surgery ,Lung Collapse ,Swine ,Biomedical Engineering ,Bronchi ,Computed tomography ,030204 cardiovascular system & hematology ,Biomaterials ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Animals ,Computer Simulation ,Bronchus ,Lung ,medicine.diagnostic_test ,Computational structural mechanics ,business.industry ,Thoracic Surgery ,General Medicine ,Bronchial occlusion ,respiratory system ,respiratory tract diseases ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Hydrodynamics ,Radiology ,Tomography, X-Ray Computed ,business - Abstract
BACKGROUND: Thoracic CO2 insufflation with positive intrathoracic pressure is usually effective during thoracoscopic surgery, however, lung collapse is sometimes insufficient. We hypothesized that inappropriate bronchial collapse might cause this unsuccessful lung collapse. OBJECTIVE: The objective of this study was to construct a computational mechanical model of bronchi for practical simulation to discover the optimal conditions of positive intrathoracic pressure during thoracoscopic surgery. METHODS: Micro-focus high-resolution X-ray computed tomography measurements of lungs from just-slaughtered swine were extracted, and the three-dimensional geometries of the bronchi under pressurized and depressurized conditions were measured accurately. The mechanical properties of the bronchus were also measured. Computational fluid dynamics (CFD) and computational structural mechanics (CSM) analyses were conducted. RESULTS: The CSM results indicated that the present structural model could simulate bronchial occlusion. The CFD results showed that airflows from pressed lung alveoli might cause low-internal-pressure regions when suddenly or heterogeneously pushed airflow was injected from a small branching bronchus to a large bronchus. A preliminary computational mechanical model of bronchi was constructed. CONCLUSIONS: We demonstrated the performance of the mechanical model of bronchi in rough simulations of bronchial occlusions. However, this model should be verified further using human data to facilitate its introduction to clinical use.
- Published
- 2021
27. A case report of late-onset schizophrenia differentiated from a dementing disorder
- Author
-
Mitsuru Hasegawa, Yoshiki Maeda, Tatsuya Nagasawa, Yasuhiro Kawasaki, Takamitsu Shimada, and Takashi Uehara
- Subjects
Late onset schizophrenia ,Aged, 80 and over ,medicine.medical_specialty ,Amyloid beta-Peptides ,Hallucinations ,business.industry ,tau Proteins ,Text mining ,Arts and Humanities (miscellaneous) ,Alzheimer Disease ,medicine ,Schizophrenia ,Humans ,Female ,Neurology (clinical) ,business ,Psychiatry ,Biomarkers ,Aged - Abstract
Background With the increase in life expectancy and the subsequent increase in the older population, the clinical importance of late-onset psychosis also increases. Neuropathological findings play an important role in the differential diagnosis of dementing disorders in older adults. Herein, we report a case of late-onset schizophrenia that required differentiation from a dementing disorder. Case presentation: The patient was an 83-year-old woman who had experienced auditory hallucinations since she was 67 years old. She was hospitalized for treatment of her psychosis. Initially, various examinations were performed to consider the possibility that she had a dementing disorder such as dementia with Lewy bodies. 123I-meta-iodobenzylguanidine myocardial scintigraphy revealed no decrease in iodine accumulation in the myocardium, and 123I-ioflupane dopamine transporter imaging revealed no decrease in dopamine transporter accumulation in the striatum. The patient had an elevated concentration of total tau (488 pg/mL), a cerebrospinal fluid biomarker. After comprehensive testing, the patient was diagnosed with late-onset schizophrenia. Her psychiatric symptoms such as auditory hallucinations diminished after the administration of the recommended first-line drug risperidone (3 mg/day), and she was discharged on day 90. Conclusions This case was identified as late-onset schizophrenia. However, an elevated total tau concentration was observed, indicating that neurofibrillary tangles and neuronal death, which are characteristic of Alzheimer 's disease, may also have been present. Late-onset schizophrenia should be treated based on an appropriate differential diagnosis, including neuropathological consideration of dementing disorders.
- Published
- 2021
28. Preoperative Arterial Embolization to Avoid Intraoperative Bleeding during Endoscopic Sinus Surgery for Organized Hematoma of the Maxillary Sinus: A Case Series and Literature Review
- Author
-
Yoshinori Tsukahara, Ayumi Ohya, Yasunari Fujinaga, Masahiro Kurozumi, Hiroaki Suzuki, Keita Tsukada, Yutaka Takumi, Jun Shinagawa, Takeshi Suzuki, Jun Miyagawa, Akira Yamada, and Takeshi Uehara
- Subjects
medicine.medical_specialty ,Maxillary sinus ,business.industry ,Arterial Embolization ,Maxillary artery ,medicine.disease ,Intraoperative bleeding ,Surgery ,Endoscopic sinus surgery ,medicine.anatomical_structure ,Hematoma ,medicine.artery ,Medicine ,business - Abstract
This study aimed to evaluate the safety and efficacy of preoperative arterial embolization of organized hematoma of the maxillary sinus.Seven patients who were pathologically diagnosed with an organized hematoma of the maxillary sinus and who underwent endoscopic sinus surgery following preoperative arterial embolization for the same from July 2013 to April 2020 at our hospital were included. A literature review of the PubMed database was performed to identify 13 cases on organized hematomas of the maxillary sinuses. The embolization and nonembolization groups comprised patients who underwent preoperative embolization (n = 10, seven from this study and three from literature) and those who did not undergo preoperative embolization (n = 10, from literature), respectively. Outcomes of embolization including embolization-related complications and postoperative bleeding were assessed, and volumes of intraoperative blood loss and duration of surgery were compared between the groups.No preoperative embolization-related complications were observed in our cases. The volume of surgical blood loss in the seven cases varied from 0 to 100 mL with a median of 30 mL, and the duration of surgery ranged from 45 to 166 minutes with a median of 112 minutes. The volume of blood loss was significantly lower for the embolization group than that for the nonembolization group (Preoperative embolization of an organized hematoma of the maxillary sinus is a safe and effective method that helps prevent serious intraoperative hemorrhage.
- Published
- 2021
29. Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting
- Author
-
Tetsuya Matoba, Satoshi Yasuda, Koichi Kaikita, Masaharu Akao, Junya Ako, Masato Nakamura, Katsumi Miyauchi, Nobuhisa Hagiwara, Kazuo Kimura, Atsushi Hirayama, Kunihiko Matsui, Hisao Ogawa, Yukihiro Koretsune, Takafumi Hiro, Tetsuya Sumiyoshi, Kazumi Kimura, Yoichiro Hashimoto, Teruyuki Hirano, Hiroyuki Daida, Yasushi Okada, Tsutomu Yamazaki, A. Nakamura, E. Tamiya, T. Yamamoto, S. Suetake, T. Noguchi, S. Nakamura, A. Matsumura, J. Kojima, S. Suwa, H. Yamaguchi, K. Kaikita, T. Yasu, A. Nakajima, T. Yamada, H. Arai, Y. Hata, T. Sakanashi, H. Tateishi, T. Nakayama, Y. Nozaki, M. Akao, Y. Okumura, M. Tokue, N. Kuroki, Y. Maruyama, T. Matoba, N. Hagiwara, H. Suzuki, Y. Nishida, M. Ajioka, K. Yumoto, S. Shimizu, T. Aoyama, H. Shimomura, T. Takeda, K. Oshiro, N. Sugishita, Y. Shibata, T. Otonari, H. Kihara, H. Ogawa, A. Ohno, M. Hazama, M. Shimizu, K. Tsukahara, S. Haruta, T. Wakeyama, T. Haruna, M. Ito, K. Fujii, N. Atsuchi, M. Sata, K. Kimura, N. Hasebe, Y. Kobayasi, K. Ohsato, K. Hironaga, Y. Naganuma, K. Anzaki, K. Oiwa, S. Okazaki, Y. Nakagawa, K. Tokuhiro, K. Tanaka, T. Momose, Y. Fukushima, R. Kametani, K. Kawamitsu, Y. Saito, S. Akashi, K. Kumagai, K. Eshima, T. Tobaru, T. Seo, K. Okuhara, K. Kozuma, Y. Ikari, T. Takahashi, I. Michishita, H. Fujikura, S. Momomura, Y. Yamamoto, K. Otomo, T. Matsubara, H. Tashiro, T. Inoue, M. Ishihara, I. Shiojima, E. Tachibana, J. Ako, K. Sumii, N. Yamamoto, N. Ohmura, T. Nakamura, Y. Morita, N. Takahashi, K. Watanabe, H. Fujinaga, M. Maruyama, T. Oka, T. Shirayama, T. Amano, K. Fukui, K. Ando, S. Oshima, S. Kagiyama, H. Teragawa, M. Yuge, S. Ono, T. Koga, K. Fujiu, M. Kuwabara, Y. Ohya, Y. Yumoto, N. Kuji, M. Ikemura, K. Kario, K. Chatani, K. Sato, H. Miyagi, M. Murakami, K. Saito, M. Hoshiga, S. Sato, N. Kubo, Y. Sakamoto, K. Ashida, H. Sakamoto, S. Murasaki, H. Uehara, T. Akasaka, Y. Ooba, S. Nakahara, Y. Hanaoka, T. Nishimiya, R. Tsunoda, Y. Onuma, S. Higuchi, A. Tani, A. Wada, M. Kato, H. Obata, Y. Higuchi, T. Endo, R. Katou, T. Matsunaga, T. Matsuoka, H. Noguchi, M. Usui, T. Hayashi, Y. Otsuji, T. Osaki, H. Zaizen, H. Yoshihara, K. Kadota, T. Hirose, T. Miyazawa, A. Mori, M. Takano, W. Shimizu, M. Wake, S. Oriso, M. Yoshiyama, S. Kakinoki, T. Nishioka, T. Ozaki, K. Nomoto, K. Seki, K. Kawai, Y. Ozaki, S. Miura, M. Kawasaki, R. Funada, K. Dote, T. Nagano, S. Okamoto, T. Kubo, Y. Murozono, T. Owada, T. Doke, T. Matsumura, M. Horiuchi, A. Takaishi, M. Yamamoto, H. Nakashima, M. Munemasa, Y. Sakata, N. Inoue, T. Ota, Y. Hamano, N. Abe, T. Tsubokura, M. Goto, I. Kubota, M. Yano, K. Umetani, T. Date, H. Morimoto, T. Noda, S. Goto, K. Hibi, A. Nakano, S. Hiramitsu, Y. Kihara, M. Sugi, N. Shiba, D. Izumi, T. Sato, S. Tayama, T. Matsui, A. Suzuki, K. Ajiki, M. Oishi, M. Kiryu, T. Ko, H. Ando, S. Miyazaki, T. Kinugawa, H. Otake, H. Kitaoka, Y. Hirata, S. Honda, M. Manita, Y. Ishii, H. Oka, Y. Nanba, M. Nishino, T. Sakamoto, T. Saito, H. Sakai, M. Ichikawa, S. Namiuchi, K. Inoue, N. Komiyama, Y. Akashi, Y. Nakamura, T. Komaru, T. Hosokawa, T. Chikamori, H. Tanaka, O. Arasaki, K. Aonuma, Y. Wakasa, T. Yoshizawa, T. Sugano, N. Yokota, A. Kakutani, T. Suzuki, Y. Abe, T. Kataoka, H. Okayama, H. Yokoi, K. Chin, K. Hasegawa, H. Tomita, H. Honzyo, H. Kawai, K. Yamamoto, Y. Morino, S. Tsujiyama, S. Hamasaki, Y. Niijima, Y. Mizuno, A. Maki, K. Tanabe, T. Murohara, S. Naomi, M. Arikawa, T. Kato, N. Matsumoto, T. Minamino, H. Sairenji, N. Miyamoto, H. Ito, Y. Matsuura, S. Hata, Y. Nakatsu, T. Onodera, M. Yoshimura, H. Amano, E. Tokutake, M. Kasao, M. Moriguchi, M. Tsuji, H. Yamamoto, Y. Yanbe, T. Iwasawa, M. Suzuki, and H. Mori
- Subjects
Rivaroxaban ,medicine.medical_specialty ,business.industry ,Unstable angina ,medicine.medical_treatment ,Percutaneous coronary intervention ,Atrial fibrillation ,medicine.disease ,Thrombosis ,Coronary artery disease ,Internal medicine ,medicine ,Cardiology ,cardiovascular diseases ,Myocardial infarction ,Cardiology and Cardiovascular Medicine ,business ,Stroke ,medicine.drug - Abstract
Objectives The aim of this AFIRE (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease) trial subgroup analysis was to examine rivaroxaban monotherapy benefits and their relation to the time between stenting and enrollment among patients after coronary stenting. Background Of 2,215 patients with atrial fibrillation and stable coronary artery disease in the AFIRE trial, rivaroxaban monotherapy was noninferior to rivaroxaban plus antiplatelet therapy (combination therapy) in terms of efficacy and superior for safety endpoints. However, thrombotic risk after antiplatelet therapy cessation remained a concern among 1,444 patients who had undergone coronary stenting >1 year before enrollment. Methods The benefits of rivaroxaban monotherapy in coronary stenting subgroups were assessed for efficacy (a composite of stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularization, or death of any cause), safety (major bleeding defined according to International Society on Thrombosis and Haemostasis criteria), ischemic endpoints, net adverse clinical event, and time between stenting and enrollment. Results Efficacy and safety endpoints for monotherapy were superior to combination therapy, with HRs of 0.70 for efficacy (95% CI: 0.50-0.98; P = 0.036) and 0.55 for safety (95% CI: 0.33-0.92; P = 0.019). For ischemic endpoints, the HR was 0.82 (95% CI: 0.58-1.15; P = 0.240). The HR became smaller with longer time between stenting and enrollment (efficacy, P for interaction = 0.158; safety, P = 0.097). Conclusions In patients with atrial fibrillation after coronary stenting, the benefits of rivaroxaban monotherapy for efficacy and safety endpoints were consistent with those in the whole AFIRE trial population. The benefits became apparent with longer time between stenting and enrollment. (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study [AFIRE]; UMIN000016612 , NCT02642419 )
- Published
- 2021
30. Pain catastrophizing hinders Disease Activity Score 28 – erythrocyte sedimentation rate remission of rheumatoid arthritis in patients with normal C‐reactive protein levels
- Author
-
Koichi Murata, Masao Tanaka, Shuichi Matsuda, Ryu Watanabe, Akio Morinobu, Tamami Yoshida, Motomu Hashimoto, Kohei Nishitani, Ritei Uehara, Hiromu Ito, Wataru Yamamoto, Go Horiguchi, and Kosaku Murakami
- Subjects
Male ,medicine.medical_specialty ,Pain ,Blood Sedimentation ,Systemic inflammation ,Severity of Illness Index ,Arthritis, Rheumatoid ,Rheumatology ,Risk Factors ,Internal medicine ,Prevalence ,medicine ,Humans ,Patient Reported Outcome Measures ,Aged ,biology ,medicine.diagnostic_test ,business.industry ,Catastrophization ,Remission Induction ,C-reactive protein ,Confounding ,Odds ratio ,Middle Aged ,medicine.disease ,Confidence interval ,C-Reactive Protein ,Cross-Sectional Studies ,Erythrocyte sedimentation rate ,Rheumatoid arthritis ,biology.protein ,Female ,Pain catastrophizing ,medicine.symptom ,business - Abstract
Aim This study aimed to assess the relationship between pain catastrophizing and achievement of 28-joint Disease Activity Score-defined remission of rheumatoid arthritis (RA), considering the presence or absence of systemic inflammation, and to evaluate associated factors for pain catastrophizing. Method This cross-sectional study included 421 RA outpatients. The relationship between pain catastrophizing and remission was analyzed by adjusting several confounding factors. Univariable and multivariable analyses were performed to determine the relationship between pain catastrophizing and RA-related factors, comorbidities, and lifestyle habits. Results The prevalence of pain catastrophizing was 26%. Pain catastrophizing was negatively associated with remission (odds ratio 0.62, 95% confidence interval 0.38-1.00, P = .048). A multinomial logistic analysis showed that the presence of pain catastrophizing was an independent factor that was negatively correlated with the achievement of remission in the absence of systemic inflammation (odds ratio 0.51, 95% confidence interval 0.28-0.93, P = .029). Factors associated with elevated ratings on the Pain Catastrophizing Scale were a history of falls within the past year, a Health Assessment Questionnaire score >0.5, and smoking habit. Further, patients' subjective symptoms, including patient global assessment minus evaluator global assessment values ≥20 and high tender joint count minus swollen joint counts, were associated with elevated pain catastrophizing. Conclusion Pain catastrophizing is a major obstacle to achieving remission in RA patients with normal C-reactive protein levels. Advanced physical disability, smoking habit, and history of falls were associated with pain catastrophizing, in addition to patients' subjective symptoms.
- Published
- 2021
31. A RAS inhibitor reduces allergic airway remodeling via regulating IL-33-derived type 2 innate lymphoid cells
- Author
-
Masaki Hanibuchi, Toshifumi Tezuka, Hisanori Uehara, Yoshinori Aono, Masahiko Azuma, Mayo Kondo, Hirohisa Ogawa, and Yasuhiko Nishioka
- Subjects
Pulmonary and Respiratory Medicine ,Clinical Biochemistry ,Spleen ,Mice ,Hypersensitivity ,Animals ,Medicine ,Lymphocytes ,Molecular Biology ,Fluticasone ,Ras Inhibitor ,Lung ,business.industry ,Innate lymphoid cell ,Airway inflammation ,respiratory system ,Interleukin-33 ,Immunity, Innate ,respiratory tract diseases ,Interleukin 33 ,medicine.anatomical_structure ,Immunology ,Airway Remodeling ,Airway ,business ,medicine.drug - Abstract
Purpose: IL-33 is known to induce corticosteroid-resistant eosinophilic inflammation and airway remodeling by activating type 2 innate lymphoid cells (ILC2s). Although the RAS signal pathway plays an important role in IL-33-induced ILC2s activation and airway remodeling, it is not known if RAS inhibitors are effective against refractory asthma. We examined the effects of the RAS inhibitor XRP44X in refractory asthma. Methods: RAS activity were examined by BAL fluid and T-cells isolated from spleen cells in Dermatophagoides pteronyssinus (Dp)-sensitized/challenged acute allergic airway inflammation model. A chronic allergic airway inflammation mouse model was generated by challenged with Dp. XRP44X and/or fluticasone were administrated nasally to different experimental groups. The effects of nasal simultaneous administration of XRP44X or fluticasone were assessed in mice administrated with IL-33 or Dp. Results: RAS activity in CD4+ T cells stimulated by Dp were suppressed by XRP44X. Although fluticasone and XRP44X only improved allergic airway inflammation in mice, XRP44X in combination with fluticasone produced further improvement in not only eosinophilic inflammation but also bronchial subepithelial thickness. XRP44X suppressed IL-5 and IL-13 production from ILC2s, although this effect was not suppressed by fluticasone. IL-33-induced airway inflammation resistant to fluticasone was ameliorated by XRP44X via regulating the accumulation of lung ILC2s. Conclusion: The RAS signal pathway plays a crucial role in allergen-induced airway remodeling associated with ILC2s. XRP44X may have therapeutic potential for refractory asthma.
- Published
- 2021
32. Efficacy of Extended Modification in Left Hemihepatectomy for Advanced Perihilar Cholangiocarcinoma
- Author
-
Masato Nagino, Tsuyoshi Igami, Yukihiro Yokoyama, S Otsuka, Yoshie Shimoyama, Nobuyuki Watanabe, Kay Uehara, Tomoki Ebata, Junpei Yamaguchi, Takashi Mizuno, and Shunsuke Onoe
- Subjects
medicine.medical_specialty ,business.industry ,medicine ,Left Hemihepatectomy ,Surgery ,Radiology ,Perihilar Cholangiocarcinoma ,business - Abstract
The aim of this study was to verify the prognostic impact of the tumor exposure at the liver transection margin (LTM) in left-sided perihilar cholangiocarcinoma and the impact of middle hepatic vein (MHV) resection on this exposure.In perihilar cholangiocarcinoma, tumors are unexpectedly exposed at the LTM during left hemihepatectomy (LH).Patients who underwent LH for perihilar cholangiocarcinoma during 2002 to 2018 were retrospectively evaluated. LH was classified into conventional and extended types, which preserved and resected the MHVs, respectively. Positive LTM was defined as the involvement of invasive carcinoma at the liver transection plane and/or the adjacent Glissonean pedicle exposed. The clinicopathologic features and survival outcomes were compared between procedures.Among 236 patients, conventional and extended LHs were performed in 198 and 38 patients, respectively. The LTM was positive in 31 (13%) patients, with an incidence of 14% versus 8% (P = 0.432) and 24% versus 0% in advanced tumors (P = 0.011). Tumor size ≥18 mm (P = 0.041), portal vein invasion (P = 0.009), and conventional LH (P = 0.028) independently predicted positive LTM. In patients with negative LTM, the survival was comparable between the two groups: 60.4% versus 59.2% at 3 years (P = 0.206), which surpassed 17.7% for those with positive LTM in the conventional group (P0.001). Multivariable analysis demonstrated that LTM status was an independent prognostic factor (P = 0.009) along with ductal margin status (P = 0.030).The LTM status is an important prognostic factor in perihilar cholangiocarcinoma. Extended LH reduced the risk of tumor exposure at the LTM with a subsequent improvement in the survival, particularly in advanced tumors.
- Published
- 2021
33. A patient with compound heterozygosity of <scp> SMPD4 </scp> : Another example of utility of exome‐based copy number analysis in autosomal recessive disorders
- Author
-
Hisato Suzuki, Taiki Shima, Mamiko Yamada, Tomoko Uehara, and Kenjiro Kosaki
- Subjects
Genetics ,business.industry ,Genetic counseling ,Copy number analysis ,Disease ,medicine.disease ,Compound heterozygosity ,Intellectual disability ,medicine ,Copy-number variation ,Allele ,business ,Exome ,Genetics (clinical) - Abstract
For the efficient diagnosis of rare and undiagnosed diseases, the parallel detection of copy number variants (CNVs) and single nucleotide variants using exome analysis is required. Recently, our group reported the usefulness of a program called EXCAVATOR2, which screens for CNVs from aligned exome data in bam format. This method is expected to contribute to the identification of structural variants and to improve the diagnosis rate, especially for the diagnosis of autosomal recessive disease, when a conventional exome analysis identifies a pathogenic variant in one allele but not the other. Here we report a 2-year-old Japanese boy with an undiagnosed disease. He had severe neonatal asphyxia, severe intellectual disability, intractable seizures, cerebellar and brainstem hypoplasia and dysmorphic features including a prominent supraorbital ridge, thin upper lip, and prominent antihelix. An exome analysis reinforced with a copy number analysis using the EXCAVATOR2 method revealed that the patient had a hemizygous variant in chr2(GRCh37):g.130925108G>A, NM_017951.4 c.832C>T, p.(Arg278*) in SMPD4 that was derived from his father and a deletion of SMPD4 derived from his mother. The presence of the deletion spanning SMPD4 was confirmed by short-read and long-read whole-genome sequencing. The successful diagnosis of this reported patient demonstrates the diagnostic utility of EXCAVATOR2 and overcomes the weakness of exome analysis for the detection of autosomal recessive diseases in nonconsanguineous families, significantly impacting genetic counseling for family planning.
- Published
- 2021
34. Reconstruction of the external auditory canal using full-thickness rolled-up skin graft after lateral temporal bone resection for T1 and T2 external auditory canal cancer
- Author
-
Natsumi Uehara, Jun Yokoi, Takeshi Fujita, Hirotaka Shinomiya, Akinobu Kakigi, Makiko Hara, Ken-ichi Nibu, and Masanori Teshima
- Subjects
Male ,medicine.medical_specialty ,Hearing loss ,medicine.medical_treatment ,Hearing Loss, Conductive ,Auditory canal ,03 medical and health sciences ,Postoperative Complications ,Tympanoplasty ,0302 clinical medicine ,medicine ,Carcinoma ,Humans ,030223 otorhinolaryngology ,Reconstruction procedure ,Ear Neoplasms ,Aged ,Aged, 80 and over ,Lateral temporal bone resection ,Squamous Cell Carcinoma of Head and Neck ,business.industry ,Temporal Bone ,Cancer ,Skin Transplantation ,General Medicine ,Middle Aged ,Plastic Surgery Procedures ,medicine.disease ,Carcinoma, Adenoid Cystic ,Surgery ,Otorhinolaryngology ,030220 oncology & carcinogenesis ,Granulation Tissue ,Audiometry, Pure-Tone ,Female ,Full thickness ,medicine.symptom ,Otologic Surgical Procedures ,business ,Ear Canal - Abstract
Objective To present our results of the external auditory canal (EAC) reconstruction procedure using rolled-up full-thickness skin graft with tympanoplasty after lateral temporal bone resection (LTBR) for early-stage EAC carcinoma. Patients and Methods A retrospective review of 15 patients who had undergone LTBR with reconstruction of the EAC for T1 and T2 EAC cancer between 2016 and 2020. Results Postoperative mean air-bone gap was 30.7 decibel hearing level. Although a few patients experienced chronic granulation, persistent otorrhea, and/or laterization of the tympanic membrane, most patients showed no serious complications related to the EAC reconstruction. Conclusion EAC reconstruction using a full-thickness skin graft in combination with tympanoplasty is useful for minimizing the hearing loss, maintaining the cosmetic appearance, and facilitating the observation into the ear cavity.
- Published
- 2021
35. Correlation between proximal serrated polyp detection and clinically significant serrated polyps: inter-endoscopist variability
- Author
-
G. Uehara-Miyagusuku, M. Astete-Benavides, C. Rodríguez-Ulloa, J. Niebuhr-Kakiuchi, H. Hernández-García, A. Nago-Nago, J Watanabe Yamamoto, G. Kishimoto-Tsukazan, G. Valladares-Álvarez, R. Komazona-Sugajara, P. Limas-Cline, V. Parra-Pérez, N. Núñez-Calixto, J. Rodríguez-Grandez, J. Pinto-Sánchez, M. Yoza-Yoshidaira, and T. Gargurevich-Sánchez
- Subjects
medicine.medical_specialty ,Adenoma ,Colon Adenoma ,Colorectal cancer ,Colonic Polyps ,Colonoscopy ,Adenoma de colon ,RC799-869 ,Logistic regression ,Gastroenterology ,Correlation ,Internal medicine ,medicine ,Humans ,Cáncer colorrectal ,Prospective Studies ,medicine.diagnostic_test ,business.industry ,Serrated polyp ,Pólipo serrato ,General Medicine ,Diseases of the digestive system. Gastroenterology ,medicine.disease ,Endoscopy ,Cross-Sectional Studies ,Colonoscopia ,Colorectal Neoplasms ,business - Abstract
Introduction and aims: The adenoma detection rate (ADR) is the most important quality indicator for the prevention of colorectal cancer but serrated polyps are also precursor lesions of the disease. The aim of our study was to compare the detection rate of proximal serrated polyps (PSPs) and that of clinically significant serrated polyps (CSSPs) between endoscopists and analyze the relation of those parameters to the ADR. Methods: An observational, prospective, cross-sectional study was conducted on all patients that underwent colonoscopy at the Policlínico Peruano Japonés within the time frame of July 2015 and August 2016. The ADR and PSP and CSSP detection rates between endoscopists were compared through multivariate logistic regression and the association between those parameters was calculated through the Pearson correlation coefficient. Results: The study included 15 endoscopists and 1,378 colonoscopies. The PSP detection rate ranged from 1.8-17% between endoscopists and had an almost perfect correlation with the CSSP detection rate (p = 0.922), as well as strongly correlating with the ADR (p = 0.769). Conclusions: There was great variability in the PSP detection rate between endoscopists. It also had an almost perfect correlation with the CSSP detection rate and strongly correlated with the ADR. Those results suggest a high CSSP miss rate at endoscopy and a low PSP detection rate. Resumen: Introducción y objetivos: La tasa de detección de adenomas (TDA) es el más importante indicador de calidad para la prevención del cáncer colorrectal. Sin embargo, los pólipos serratos también son lesiones precursoras de cáncer colorrectal. El objetivo del estudio fue comparar la tasa de detección de pólipos serratos proximales (PSP) y la tasa de detección de pólipos serratos clínicamente significativos (PSCS) entre endoscopistas, y analizar la relación entre estos parámetros y la TDA. Métodos: Estudio observacional, transversal y prospectivo. Se incluyeron a todos los pacientes que acudieron para colonoscopia al Policlínico Peruano Japonés entre julio del 2015 y agosto del 2016. Se utilizó regresión logística multivariada para comparar la TDA, la tasa detección de PSP y la tasa de detección de PSCS entre los endoscopistas. Se calculó la asociación entre estos parámetros mediante el coeficiente de correlación de Pearson. Resultados: Fueron incluidos 15 endoscopistas y 1378 colonoscopias. La tasa de detección de PSP estuvo en el rango de 1,8-17% entre los endoscopistas. La tasa de detección de PSP tuvo una correlación casi perfecta con la tasa de detección de PSCS (ρ = 0,922). La tasa de detección de PSP tuvo una fuerte correlación con la TDA (ρ = 0,769). Conclusiones: La tasa de detección de PSP tiene gran variabilidad entre endoscopistas, y tiene una correlación casi perfecta con la tasa de detección de PSCS, y una fuerte correlación con la TDA. Estos resultados sugieren una alta tasa de PSCS perdidos por los endoscopistas con una baja tasa de detección de PSP.
- Published
- 2021
36. MRI and CT features of a malignant myoepithelioma of the scrotum: A case report and literature review
- Author
-
Yuichi Kojima, Yasumasa Monobe, Katsuya Kato, Takayoshi Shinya, Shinya Uehara, and Hideyo Fujiwara
- Subjects
medicine.medical_specialty ,endocrine system ,endocrine system diseases ,R895-920 ,Case Report ,urologic and male genital diseases ,Medical physics. Medical radiology. Nuclear medicine ,Scrotum ,medicine ,Effective diffusion coefficient ,Radiology, Nuclear Medicine and imaging ,Computed tomography ,Malignant myoepithelioma ,medicine.diagnostic_test ,business.industry ,urogenital system ,Myoepithelial cell ,Magnetic resonance imaging ,medicine.disease ,Scrotum, Magnetic resonance imaging ,Dynamic contrast-enhanced MRI ,medicine.anatomical_structure ,Malignant Myoepithelioma ,Radiology ,Diffusion-weighted imaging ,business ,Calcification ,Diffusion MRI - Abstract
Malignant myoepithelioma of the scrotum is extremely rare. We report the case of a 51-year-old man with malignant myoepithelioma of the scrotum, wherein computed tomography and magnetic resonance imaging revealed a lobulated soft tissue mass with calcification, cystic component, and solid component with gradual contrast enhancement on dynamic contrast-enhanced scans. The patient presented with scrotal induration, and there was no elevation of tumor markers and no evidence of a metastatic lesion on computed tomography and magnetic resonance imaging. Histopathological examination of the resected scrotal specimen confirmed a well-circumscribed solid tumor with septa, a small area of hemorrhage, and necrosis. The subsequent diagnosis was malignant myoepithelioma of the scrotum. This case shows that scrotal malignant myoepithelioma might appear as a well-defined lobulated mass with cystic regions. We conjecture that the enhancement pattern and apparent diffusion coefficient values can be potential markers for scrotal myoepithelial tumors.
- Published
- 2021
37. Clinicopathological and prognostic significance of immunophenotypic characterization of endocervical adenocarcinoma using CLDN18, CDH17, and PAX8 in association with HPV status
- Author
-
Shiho Asaka, Tsutomu Miyamoto, Masayuki Ito, Hiroyoshi Ota, Tomoyuki Nakajima, Chinatsu Kobayashi, Koichi Ida, Takeshi Uehara, and Ryoichi Asaka
- Subjects
medicine.medical_specialty ,Lymphovascular invasion ,Uterine Cervical Neoplasms ,Adenocarcinoma ,Gastroenterology ,Pathology and Forensic Medicine ,PAX8 Transcription Factor ,Immunophenotyping ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Molecular Biology ,business.industry ,Papillomavirus Infections ,Not Otherwise Specified ,HPV infection ,Cell Biology ,General Medicine ,Cadherins ,Prognosis ,medicine.disease ,digestive system diseases ,Lobular Endocervical Glandular Hyperplasia ,Claudins ,Immunohistochemistry ,Female ,business ,PAX8 - Abstract
In 2020, the WHO published a new system for classifying invasive endocervical adenocarcinoma based on histological features and high-risk human papillomavirus (HPV) infection. However, immunophenotypes of each histological subtype require further investigation. We immunohistochemically analyzed 66 invasive endocervical adenocarcinomas using three cell-lineage–specific markers: claudin 18 (CLDN18) for gastric, cadherin 17 (CDH17) for intestinal, and PAX8 for Mullerian epithelial cells. We identified five immunophenotypes of endocervical adenocarcinoma: gastric (21%); intestinal (14%); gastrointestinal (11%); Mullerian (35%); and not otherwise specified (NOS) (20%). Adenocarcinomas with gastric immunophenotype, characterized by aging (p = 0.0050), infrequent HPV infection (p
- Published
- 2021
38. Pseudohypoxic brain swelling and secondary hydrocephalus with pseudomeningocele after lumbar surgery: a case report
- Author
-
Satoshi Nakao, Yasunari Fujinaga, Yujiro Hamano, Tomoki Kaneko, Jun Takahashi, Minori Kodaira, Masafumi Kuroiwa, Shugo Kuraishi, Mikito Kawamata, Takahiro Tsutsumimoto, Michitaro Ichikawa, Yoshinari Miyaoka, Hiroki Oba, Satoshi Tanaka, Shota Ikegami, Toshimasa Futatsugi, Hiroshi Imamura, Takayuki Kamanaka, Takahiro Maruyama, Masashi Uehara, Tetsuyoshi Horiuchi, and Yoshiki Sekijima
- Subjects
medicine.medical_specialty ,business.industry ,General Medicine ,medicine.disease ,Hypoxic Ischemic Encephalopathy ,Hydrocephalus ,Surgery ,Shunt (medical) ,Pseudomeningocele ,Neuroimaging ,Lumbar surgery ,medicine ,Lumbar spine surgery ,Brain swelling ,Neurology (clinical) ,business - Abstract
Background Postoperative intracranial complications are rare in spine surgery not including cranial procedures. We describe an uncommon case of pseudohypoxic brain swelling (PHBS) and secondary hydrocephalus after transforaminal lumbar interbody fusion (TLIF) presenting as impaired consciousness and repeated seizures. Case presentation A 65-year-old man underwent L4-5 TLIF for lumbar spondylolisthesis and began experiencing generalized seizures immediately postoperatively. Computed tomography (CT) revealed diffuse cerebral edema-like hypoxic ischemic encephalopathy. He was transported to our hospital, at which time epidural drainage was halted and anti-edema therapy was commenced. His impaired consciousness improved. However, he suffered secondary hydrocephalus due to continuous bleeding from a dural defect and spinal epidural fluid collection 3 months later. Following the completion of dural repair and insertion of a ventriculoperitoneal shunt, his neurologic symptoms and neuroimaging findings improved significantly. Conclusions PHBS can be considered in patients with unexpected neurological deterioration following lumbar spine surgery even with the absence of documented durotomy. This might be due to postoperative intracranial hypotension-associated venous congestion, and to be distinguished from the more common postoperative cerebral ischemic events-caused by arterial or venous occlusions-or anesthetics complications.
- Published
- 2021
39. Persistent Hyperplastic Primary Vitreous with Microphthalmia and Coloboma in a Patient with Okur-Chung Neurodevelopmental Syndrome
- Author
-
Yukiko Kuroda, Mizuki Asano, Noriko Aida, Hiroaki Murakami, Kenjiro Kosaki, Tatsuro Kumaki, Naoto Nishimura, Kenji Kurosawa, Tomoko Uehara, and Yumi Enomoto
- Subjects
medicine.medical_specialty ,Coloboma ,Novel Insights from Clinical Practice ,Persistent hyperplastic primary vitreous ,business.industry ,Ophthalmology ,Genetics ,medicine ,medicine.disease ,business ,Microphthalmia ,Genetics (clinical) - Abstract
Okur-Chung neurodevelopmental syndrome is a rare autosomal dominant disorder caused by pathogenic variants in CSNK2A1, which encodes the alpha 1 catalytic subunit of casein kinase II. This syndrome is characterized by intellectual disability, developmental delay, and multisystemic abnormalities including those of the brain, extremities, and skin as well as cardiovascular, gastrointestinal, and immune systems. In this study, we describe a 5-year-old boy with a de novo novel nonsense variant in CSNK2A1, NM_001895.3:c.319C>T (p.Arg107*). He showed bilateral persistent hyperplastic primary vitreous with microphthalmia, lens dysplasia, and coloboma. Ocular manifestations are very rare in this syndrome, and this study expands the spectrum of the clinical presentations of this syndrome.
- Published
- 2021
40. Intraoperative Cone Beam CT in Hybrid Operation Room for Pediatric Scoliosis Patients
- Author
-
Tetsuhiko Mimura, Yoshinari Miyaoka, Terue Hatakenaka, Masahiro Fujii, Masashi Uehara, Takashi Takizawa, Jun Takahashi, Jun Miyagawa, Ryo Munakata, Hiroki Oba, Shugo Kuraishi, Yusuke Tanikawa, Koseki Michihiko, Takayuki Kamanaka, and Shota Ikegami
- Subjects
Male ,Cone beam computed tomography ,Adolescent ,medicine.medical_treatment ,Perforation (oil well) ,Scoliosis ,Radiation ,Radiation Dosage ,Pedicle Screws ,medicine ,Humans ,Orthopedics and Sports Medicine ,Child ,Pedicle screw ,Retrospective Studies ,business.industry ,Retrospective cohort study ,Cone-Beam Computed Tomography ,medicine.disease ,Vertebra ,Spinal Fusion ,medicine.anatomical_structure ,Surgery, Computer-Assisted ,Spinal fusion ,Female ,Neurology (clinical) ,Tomography, X-Ray Computed ,Nuclear medicine ,business - Abstract
Study design Retrospective observational study. Objective This study aimed to determine the effect of reducing the radiation dose of intraoperative cone beam computed tomography (CBCT) during posterior spinal fusion (PSF) for pediatric scoliosis on the rate of pedicle screw (PS) violation. Summary of background data Intraoperative CBCT for pediatric scoliosis improves the accuracy of PS insertion in PSF. However, few reports have addressed the PS perforation rate from reduced radiation doses in hybrid navigation. Methods We evaluated 855 PSs inserted into 58 pediatric scoliosis patients (11 male and 47 female, mean age: 16.6 years) who underwent PSF using CBCT. A radiation dose of 1/3 or 1/5 of the normal dose (ND) was defined as a low dose (LD). After PS insertion, intraoperative CBCT images were reviewed to assess the degree of PS perforation. G2-3 (i.e., perforations of 4 mm or more) was defined as a violation. The PS violation rate was compared between the groups, and factors associated with violations were examined. Results A total of 567 and 288 screws were inserted in the ND group and LD group, respectively. The PS violation rate was comparable at 1.8% in the ND group and 1.7% in the LD group. Multiple logistic regression analysis showed that distance from the upper instrumented vertebra (UIV) was an independently associated factor of PS violation (+1 vertebra, OR 0.73, P = 0.038). In addition, the mean height of patients with PS violations (148.8 ± 3.6 cm) was significantly shorter than that of patients without violations (157.9 ± 1.2 cm) (P = 0.034). Conclusion There was no increase in PS violation rate with lower doses of radiation for intraoperative navigation CBCT. Extra care is warranted for vertebrae close to the UIV and patients of shorter stature.Level of Evidence: 3.
- Published
- 2021
41. Hemodialysis Initiation in Oldest-Old Patients: A Case Series
- Author
-
Haruhito Azuma, Haruhiko Onaka, Ryoichi Maenosono, Kazuki Nishimura, Kazumasa Komura, Hirofumi Uehara, Yuki Yoshikawa, and Tomohisa Matsunaga
- Subjects
Gerontology ,education.field_of_study ,hemodialysis ,end-stage renal disease ,business.industry ,medicine.medical_treatment ,Population ,japan ,Oldest old ,Diseases of the genitourinary system. Urology ,End stage renal disease ,oldest-old ,Quality of life ,Nephrology ,medicine ,Elderly people ,Case Series ,In patient ,RC870-923 ,Hemodialysis ,education ,business ,Dialysis - Abstract
With an increase in the number of older adults worldwide, the oldest-old population, defined as individuals over the age of 90, is also growing. Japan is now facing the problem of a “super-aged society” in which over 21% of the population is aged over 65. The oldest-old constituted 1.8% (2.31 million) of the Japanese population in 2019. Such individuals have special health-care needs. In cases of acute or chronic (or both) renal failure in the oldest-old, it becomes difficult to decide whether dialysis should be initiated. The issue is controversial, and there is some debate on whether dialysis should be avoided in elderly people because of their frailty or if it should be initiated to enable them to spend their remaining years with their families by improving their quality of life. Herein, we describe our experience in 4 cases of hemodialysis initiated in patients over the age of 90. In our experience, dialysis enabled them to spend the rest of their lives with their families, which could not have been possible without it. Although further studies are needed, we concluded that oldest-old individuals in good general health could be eligible for and benefit from hemodialysis.
- Published
- 2021
42. Exosomal miR-214-3p as a potential novel biomarker for rhabdoid tumor of the kidney
- Author
-
Shota Uekusa, Eri Nagasaki-Maeoka, Kohei Hijikata, Shuichiro Uehara, Kyoko Fujiwara, Bin Yamaoka, Reona Kato, Ayano Hidaka, and Tsugumichi Koshinaga
- Subjects
Exosomes ,Exosome ,Mice ,Cell Line, Tumor ,Neuroblastoma ,microRNA ,Biomarkers, Tumor ,medicine ,Animals ,Humans ,Child ,miR-214 ,business.industry ,fungi ,Cancer ,General Medicine ,medicine.disease ,Embryonic stem cell ,Kidney Neoplasms ,MicroRNAs ,Pediatrics, Perinatology and Child Health ,Cancer research ,Biomarker (medicine) ,Surgery ,Cancer biomarkers ,business - Abstract
Rhabdoid tumor of the kidney (RTK) is a rare, highly aggressive pediatric renal tumor. No specific biomarkers are available for detection of RTK, and the initial differential diagnosis from other pediatric abdominal tumors, including neuroblastoma (NB), is difficult. Exosomal miRNAs are novel cancer biomarkers that can be detected in biological fluids. We explored candidate RTK-specific exosomal miRNAs as novel biomarkers of RTK. Exosomal miRNAs were collected from conditioned media of human RTK-derived cell lines, a human embryonic renal cell line, and human NB-derived cell lines. miRNA sequencing (miRNA-Seq) was performed to detect candidate RTK-specific exosomal miRNAs. The exosomal miRNA expression in conditioned media of tumor cell lines and serum from RTK xenograft-bearing mice was analyzed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The expression of exosomal miR-214-3p detected by miRNA-Seq was highest in RTK-derived cell lines. Exosomal miR-214-3p expression level determined by qRT-PCR was significantly higher in RTK-derived cell lines than in the human embryonic renal cell line or NB-derived cell lines. Furthermore, the serum exosomal miR-214-3p expression level was significantly higher in RTK xenograft mice than controls. Our data indicated that exosomal miR-214-3p has potential as a novel biomarker of RTK.
- Published
- 2021
43. Abundant TNF-LIGHT expression in the airways of patients with asthma with persistent airflow limitation: Association with nitrative and inflammatory profiles
- Author
-
Kazuki Matsuda, Keiko Doi, Sho Uehara, Shuichiro Ohata, Nobutaka Edakuni, Yoriyuki Murata, Kazuki Hamada, Yuichi Ohteru, Ayumi Chikumoto, Keita Murakawa, Misa Harada, Tsunahiko Hirano, Junki Suizu, Keiji Oishi, Kazuto Matsunaga, Yoshikazu Yamaji, and Maki Asami-Noyama
- Subjects
Pulmonary and Respiratory Medicine ,Tumor Necrosis Factor Ligand Superfamily Member 14 ,Respiratory System ,chemistry.chemical_compound ,Forced Expiratory Volume ,medicine ,Humans ,Reactive nitrogen species ,Asthma ,business.industry ,Sputum ,medicine.disease ,humanities ,respiratory tract diseases ,Staining ,Eosinophils ,Secretory protein ,chemistry ,Immunology ,Matrix Metalloproteinase 2 ,Immunohistochemistry ,Tumor necrosis factor alpha ,medicine.symptom ,Airway ,business - Abstract
Background The role of the inflammatory secretory protein TNF-LIGHT (LIGHT) in the molecular mechanisms underlying persistent airflow limitation (PAL) in asthma remains unclear. We hypothesized that high airway LIGHT expression may be a feature of asthma with PAL associated with specific expression patterns of inflammatory molecules. Methods This hypothesis was tested in 16 patients with asthma on inhaled corticosteroid treatment. Induced sputum was collected, the expression of LIGHT and 3-nitrotyrosine (NT), which reflects the footprint of reactive nitrogen species content, was measured using immunohistochemical staining, and the inflammatory molecules in the sputum supernatant were analyzed using a magnetic bead array. Results LIGHT staining in the cells had a significantly higher intensity in participants with PAL than in participants without PAL (47.9 × 104/ml vs. 5.4 × 104/ml; p Conclusions The findings suggest that LIGHT is a key component in the association between airway inflammation and airflow limitation in patients with asthma, and its expression may be persistently correlated with the abundance of inflammatory cells and inflammatory and profibrogenic radical/molecules.
- Published
- 2021
44. Management strategies for patients with advanced rectal cancer and liver metastases using modified Delphi methodology: results from the PelvEx Collaborative
- Author
-
Kelly M. E., Agj A., Abdul Aziz N., Abecasis N., Abraham-Nordling M., Akiyoshi T., Alberda W., Albert M., Andric M., Angenete E., Antoniou A., Auer R., Austin K. K., Aziz O., Baker R. P., Bali M., Baseckas G., Bebington B., Bednarski B. K., Beets G. L., Berg P. L., Beynon J., Biondo S., Boyle K., Bordeianou L., Bremers A. B., Brunner M., Buchwald P., Bui A., Burgess A., Jwa B., Burling D., Campain N., Carvalhal S., Castro L., Caycedo-Marulanda A., Kkl C., Chang G. J., Chew M. H., Chong P., Christensen H. K., Clouston H., Codd M., Collins D., Colquhoun A. J., Corr A., Coscia M., Coyne P. E., Creavin B., Croner R. S., Damjanovic L., Daniels I. R., Davies M., Davies R. J., Delaney C. P., de Wilt J., Denost Q., Deutsch C., Dietz D., Domingo S., Dozois E. J., Duff M., Eglinton T., Enrique-Navascues J. M., Espin-Basany E., Evans M. D., Fearnhead N. S., Flatmark K., Fleming F., Frizelle F. A., Gallego M. A., Garcia-Granero E., Garcia-Sabrido J. L., Gentilini L., George M. L., Ghouti L., Giner F., Ginther N., Glynn R., Golda T., Griffiths B., Harris D. A., Jaw H., Hanchanale V., Harji D. P., Helewa R. M., Heriot A. G., Hochman D., Hohenberger W., Holm T., Hompes R., Jenkins J. T., Kaffenberger S., Kandaswamy G. V., Kapur S., Kanemitsu Y., Kelley S. R., Keller D. S., Khan M. S., Kiran R. P., Kim H., Kim H. J., Koh C. E., Nfm K., Kokelaar R., Kontovounisios C., Kristensen H. O., Kroon H. M., Kusters M., Lago V., Larsen S. G., Larson D. W., Law W. L., Laurberg S., Lee P. J., Limbert M., Lydrup M. L., Lyons A., Lynch A. C., Mantyh C., Mathis K. L., Cfs M., Martling A., Wjhj M., Merkel S., Mehta A. M., McArthur D. R., McDermott F. D., McGrath J. S., Malde S., Mirnezami A., Jrt M., Morton J. R., Mullaney T. G., Negoi I., Jwm N., Nguyen B., Nielsen M. B., Gap N., Nilsson P. J., O'Connell P. R., O'Dwyer S. T., Palmer G., Pappou E., Park J., Patsouras D., Pellino G., Peterson A. C., Poggioli G., Proud D., Quinn M., Quyn A., Radwan R. W., Rasheed S., Rasmussen P. C., Regenbogen S. E., Renehan A., Rocha R., Rochester M., Rohila J., Rothbarth J., Rottoli M., Roxburgh C., Hjt R., Ryan E. J., Safar B., Sagar P. M., Sahai A., Saklani A., Sammour T., Sayyed R., Amp S., Schwarzkopf E., Scripcariu V., Selvasekar C., Shaikh I., Shellawell G., Shida D., Simpson A., Smart N. J., Smart P., Smith J. J., Solbakken A. M., Solomon M. J., Sorensen M. M., Steele S. R., Steffens D., Stitzenberg K., Stocchi L., Stylianides N. A., Sumrien H., Sutton P. A., Swartking T., Taylor C., Tekkis P. P., Teras J., Thurairaja R., Toh E. L., Tsarkov P., Tsukada Y., Tsukamoto S., Tuech J. J., Turner W. H., Tuynman J. B., van Ramshorst G., van Zoggel D., Vasquez-Jimenez W., Verhoef C., Vizzielli G., Elk V., Uehara K., Wakeman C., Warrier S., Wasmuth H. H., Weber K., Weiser M. R., Jmd W., Wild J., Wilson M., Wolthuis A., Yano H., Yip B., Yip J., Yoo R. N., Winter D. C., Rottoli M, Poggioli G, Kelly, M. E., Agj, A., Abdul Aziz, N., Abecasis, N., Abraham-Nordling, M., Akiyoshi, T., Alberda, W., Albert, M., Andric, M., Angenete, E., Antoniou, A., Auer, R., Austin, K. K., Aziz, O., Baker, R. P., Bali, M., Baseckas, G., Bebington, B., Bednarski, B. K., Beets, G. L., Berg, P. L., Beynon, J., Biondo, S., Boyle, K., Bordeianou, L., Bremers, A. B., Brunner, M., Buchwald, P., Bui, A., Burgess, A., Jwa, B., Burling, D., Campain, N., Carvalhal, S., Castro, L., Caycedo-Marulanda, A., Kkl, C., Chang, G. J., Chew, M. H., Chong, P., Christensen, H. K., Clouston, H., Codd, M., Collins, D., Colquhoun, A. J., Corr, A., Coscia, M., Coyne, P. E., Creavin, B., Croner, R. S., Damjanovic, L., Daniels, I. R., Davies, M., Davies, R. J., Delaney, C. P., de Wilt, J., Denost, Q., Deutsch, C., Dietz, D., Domingo, S., Dozois, E. J., Duff, M., Eglinton, T., Enrique-Navascues, J. M., Espin-Basany, E., Evans, M. D., Fearnhead, N. S., Flatmark, K., Fleming, F., Frizelle, F. A., Gallego, M. A., Garcia-Granero, E., Garcia-Sabrido, J. L., Gentilini, L., George, M. L., Ghouti, L., Giner, F., Ginther, N., Glynn, R., Golda, T., Griffiths, B., Harris, D. A., Jaw, H., Hanchanale, V., Harji, D. P., Helewa, R. M., Heriot, A. G., Hochman, D., Hohenberger, W., Holm, T., Hompes, R., Jenkins, J. T., Kaffenberger, S., Kandaswamy, G. V., Kapur, S., Kanemitsu, Y., Kelley, S. R., Keller, D. S., Khan, M. S., Kiran, R. P., Kim, H., Kim, H. J., Koh, C. E., Nfm, K., Kokelaar, R., Kontovounisios, C., Kristensen, H. O., Kroon, H. M., Kusters, M., Lago, V., Larsen, S. G., Larson, D. W., Law, W. L., Laurberg, S., Lee, P. J., Limbert, M., Lydrup, M. L., Lyons, A., Lynch, A. C., Mantyh, C., Mathis, K. L., Cfs, M., Martling, A., Wjhj, M., Merkel, S., Mehta, A. M., Mcarthur, D. R., Mcdermott, F. D., Mcgrath, J. S., Malde, S., Mirnezami, A., Jrt, M., Morton, J. R., Mullaney, T. G., Negoi, I., Jwm, N., Nguyen, B., Nielsen, M. B., Gap, N., Nilsson, P. J., O'Connell, P. R., O'Dwyer, S. T., Palmer, G., Pappou, E., Park, J., Patsouras, D., Pellino, G., Peterson, A. C., Poggioli, G., Proud, D., Quinn, M., Quyn, A., Radwan, R. W., Rasheed, S., Rasmussen, P. C., Regenbogen, S. E., Renehan, A., Rocha, R., Rochester, M., Rohila, J., Rothbarth, J., Rottoli, M., Roxburgh, C., Hjt, R., Ryan, E. J., Safar, B., Sagar, P. M., Sahai, A., Saklani, A., Sammour, T., Sayyed, R., Amp, S., Schwarzkopf, E., Scripcariu, V., Selvasekar, C., Shaikh, I., Shellawell, G., Shida, D., Simpson, A., Smart, N. J., Smart, P., Smith, J. J., Solbakken, A. M., Solomon, M. J., Sorensen, M. M., Steele, S. R., Steffens, D., Stitzenberg, K., Stocchi, L., Stylianides, N. A., Sumrien, H., Sutton, P. A., Swartking, T., Taylor, C., Tekkis, P. P., Teras, J., Thurairaja, R., Toh, E. L., Tsarkov, P., Tsukada, Y., Tsukamoto, S., Tuech, J. J., Turner, W. H., Tuynman, J. B., van Ramshorst, G., van Zoggel, D., Vasquez-Jimenez, W., Verhoef, C., Vizzielli, G., Elk, V., Uehara, K., Wakeman, C., Warrier, S., Wasmuth, H. H., Weber, K., Weiser, M. R., Jmd, W., Wild, J., Wilson, M., Wolthuis, A., Yano, H., Yip, B., Yip, J., Yoo, R. N., Winter, D. C., and Academic Medical Center
- Subjects
Liver metastasisSurvival Outcome ,medicine.medical_specialty ,survival outcomes ,Colorectal cancer ,surgical outcome ,medicine.medical_treatment ,Delphi method ,Rectum ,Disease ,surgical outcomes ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Hepatectomy ,Humans ,Medicine ,liver metastasi ,Rectal cancer ,Neoplasm Staging ,Pelvic exenteration ,Rectal Neoplasms ,business.industry ,General surgery ,Liver Neoplasms ,Gastroenterology ,Induction chemotherapy ,medicine.disease ,liver metastasis ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,international collaboration ,030211 gastroenterology & hepatology ,business - Abstract
Aim: A total of 15–20% of patients with rectal cancer have liver metastases on presentation. The management of these patients is controversial. Heterogeneity in management strategies is considerable, with management often being dependent on local resources and available expertise. Method: Members of the PelvEx Collaborative were invited to participate in the generation of a consensus statement on the optimal management of patients with advanced rectal cancer with liver involvement. Fifteen statements were created for topical discussion on diagnostic and management issues. Panellists were asked to vote on statements and anonymous feedback was given. A collaborative meeting was used to discuss any nuances and clarify any obscurity. Consensus was considered when > 85% agreement on a statement was achieved. Results: A total of 135 participants were involved in the final round of the Delphi questionnaire. Nine of the 15 statements reached consensus regarding the management of patients with advanced rectal cancer and oligometastatic liver disease. Routine use of liver MRI was not recommended for patients with locally advanced rectal cancer, unless there was concern for metastatic disease on initial computed tomography staging scan. Induction chemotherapy was advocated as first-line treatment in those with synchronous liver metastases in locally advanced rectal cancer. In the presence of symptomatic primary disease, a diverting stoma may be required to facilitate induction chemotherapy. Overall, only one-quarter of the panellists would consider simultaneous pelvic exenteration and liver resection. Conclusion: This Delphi process highlights the diverse treatment of advanced rectal cancer with liver metastases and provides recommendations from an experienced international group regarding the multidisciplinary management approach.
- Published
- 2020
45. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
- Author
-
Subodh Verma, Nitish K Dhingra, Javed Butler, Stefan D Anker, Joao Pedro Ferreira, Gerasimos Filippatos, James L Januzzi, Carolyn S P Lam, Naveed Sattar, Barbara Peil, Matias Nordaby, Martina Brueckmann, Stuart J Pocock, Faiez Zannad, Milton Packer, M Packer, S Anker, J Butler, G Filippatos, S Pocock, F Zannad, JP Ferreira, M Brueckmann, J George, W Jamal, FK Welty, M Palmer, T Clayton, KG Parhofer, TR Pedersen, B Greenberg, MA Konstam, KR Lees, P Carson, W Doehner, A Miller, M Haas, S Pehrson, M Komajda, I Anand, J Teerlink, A Rabinstein, T Steiner, H Kamel, G Tsivgoulis, J Lewis, J Freston, N Kaplowitz, J Mann, J Petrie, S Perrone, S Nicholls, S Janssens, E Bocchi, N Giannetti, S Verma, J Zhang, J Spinar, M-F Seronde, M Boehm, B Merkely, V Chopra, M Senni, S Taddi, H Tsutsui, D-J Choi, E Chuquiure, HPB La Rocca, P Ponikowski, JRG Juanatey, I Squire, J Januzzi, I Pina, R Bernstein, A Cheung, J Green, S Kaul, C Lam, G Lip, N Marx, P McCullough, C Mehta, J Rosenstock, N Sattar, B Scirica, S Shah, C Wanner, D Aizenberg, L Cartasegna, F Colombo Berra, H Colombo, M Fernandez Moutin, J Glenny, C Alvarez Lorio, D Anauch, R Campos, A Facta, A Fernandez, R Ahuad Guerrero, L Lobo Márquez, RA Leon de la Fuente, M Mansilla, M Hominal, E Hasbani, M Najenson, G Moises Azize, H Luquez, L Guzman, H Sessa, M Amuchástegui, O Salomone, E Perna, D Piskorz, M Sicer, D Perez de Arenaza, C Zaidman, S Nani, C Poy, J Resk, R Villarreal, C Majul, T Smith Casabella, S Sassone, A Liberman, G Carnero, A Caccavo, M Berli, N Budassi, J Bono, A Alvarisqueta, J Amerena, K Kostner, A Hamilton, A Begg, J Beltrame, D Colquhoun, G Gordon, A Sverdlov, G Vaddadi, J Wong, J Coller, D Prior, A Friart, A Leone, G Vervoort, P Timmermans, P Troisfontaines, C Franssen, T Sarens, H Vandekerckhove, P Van De Borne, F Chenot, J De Sutter, E De Vuyst, P Debonnaire, M Dupont, O Pereira Dutra, LH Canani, MdC Vieira Moreira, W de Souza, LM Backes, L Maia, B De Souza Paolino, ER Manenti, W Saporito, F Villaça Guimarães Filho, T Franco Hirakawa, LA Saliba, FC Neuenschwander, CA de Freitas Zerbini, G Gonçalves, Y Gonçalves Mello, J Ascenção de Souza, L Beck da Silva Neto, EA Bocchi, J Da Silveira, JB de Moura Xavier Moraes Junior, JD de Souza Neto, M Hernandes, HC Finimundi, CR Sampaio, E Vasconcellos, FJ Neves Mancuso, MM Noya Rabelo, M Rodrigues Bacci, F Santos, M Vidotti, MV Simões, FL Gomes, C Vieira Nascimento, D Precoma, FA Helfenstein Fonseca, JA Ribas Fortes, PE Leães, D Campos de Albuquerque, JF Kerr Saraiva, S Rassi, FA Alves da Costa, G Reis, S Zieroth, D Dion, D Savard, R Bourgeois, C Constance, K Anderson, M-H Leblanc, D Yung, E Swiggum, L Pliamm, Y Pesant, B Tyrrell, T Huynh, J Spiegelman, J-P Lavoie, M Hartleib, R Bhargava, L Straatman, S Virani, A Costa-Vitali, L Hill, M Heffernan, Y Khaykin, J Ricci, M Senaratne, A Zhai, B Lubelsky, M Toma, L Yao, R McKelvie, L Noronha, M Babapulle, A Pandey, G Curnew, A Lavoie, J Berlingieri, S Kouz, E Lonn, R Chehayeb, Y Zheng, Y Sun, H Cui, Z Fan, X Han, X Jiang, Q Tang, J Zhou, Z Zheng, X Zhang, N Zhang, Y Zhang, A Shen, J Yu, J Ye, Y Yao, J Yan, X Xu, Z Wang, J Ma, Y Li, S Li, S Lu, X Kong, Y Song, G Yang, Z Yao, Y Pan, X Guo, Z Sun, Y Dong, J Zhu, D Peng, Z Yuan, J Lin, Y Yin, O Jerabek, H Burianova, T Fiala, J Hubac, O Ludka, Z Monhart, P Vodnansky, K Zeman, D Foldyna, J Krupicka, I Podpera, L Busak, M Radvan, Z Vomacka, R Prosecky, R Cifkova, V Durdil, J Vesely, J Vaclavik, P Cervinka, A Linhart, T Brabec, R Miklik, H Bourhaial, H-G Olbrich, S Genth-Zotz, E Kemala, B Lemke, M Böhm, S Schellong, W Rieker, T Heitzer, H Ince, M Faghih, A Birkenfeld, A Begemann, A Ghanem, A Ujeyl, S von Haehling, T Dorsel, J Bauersachs, M Prull, F Weidemann, H Darius, G Nickenig, A Wilke, J Sauter, U Rauch-Kroehnert, N Frey, CP Schulze, W König, L Maier, F Menzel, N Proskynitopoulos, H-H Ebert, H-E Sarnighausen, H-D Düngen, M Licka, C Stellbrink, B Winkelmann, N Menck, JL López-Sendón, L de la Fuente Galán, JF Delgado Jiménez, N Manito Lorite, M Pérez de Juan Romero, E Galve Basilio, F Cereto Castro, JR González Juanatey, JJ Gómez, M Sanmartín Fernández, X Garcia-Moll Marimon, D Pascual Figal, R Bover Freire, E Bonnefoy Cudraz, A Jobbe Duval, D Tomasevic, G Habib, R Isnard, F Picard, P Khanoyan, J-L Dubois-Rande, M Galinier, F Roubille, J Alexandre, D Babuty, N Delarche, J-B Berneau, N Girerd, M Saxena, G Rosano, Z Yousef, C Clifford, C Arden, A Bakhai, C Boos, G Jenkins, C Travill, D Price, L Koenyves, F Lakatos, A Matoltsy, E Noori, Z Zilahi, P Andrassy, S Kancz, G Simon, T Sydo, A Vorobcsuk, RG Kiss, K Toth, I Szakal, L Nagy, T Barany, A Nagy, E Szolnoki, VK Chopra, S Mandal, V Rastogi, B Shah, A Mullasari, J Shankar, V Mehta, A Oomman, U Kaul, S Komarlu, D Kahali, A Bhagwat, V Vijan, NK Ghaisas, A Mehta, J Kashyap, Y Kothari, S TaddeI, M Scherillo, V Zacà, S Genovese, A Salvioni, A Fucili, F Fedele, F Cosmi, M Volpe, C Mazzone, G Esposito, M Doi, H Yamamoto, S Sakagami, S Oishi, Y Yasaka, H Tsuboi, Y Fujino, S Matsuoka, Y Watanabe, T Himi, T Ide, M Ichikawa, Y Kijima, T Koga, S Yuda, K Fukui, T Kubota, M Manita, H Fujinaga, T Matsumura, Y Fukumoto, R Kato, Y Kawai, G Hiasa, Y Kazatani, M Mori, A Ogimoto, M Inoko, M Oguri, M Kinoshita, K Okuhara, N Watanabe, Y Ono, K Otomo, Y Sato, T Matsunaga, A Takaishi, N Miyagi, H Uehara, H Takaishi, H Urata, T Kataoka, H Matsubara, T Matsumoto, T Suzuki, N Takahashi, M Imamaki, T Yoshitama, T Saito, H Sekino, Y Furutani, M Koda, T Shinozaki, K Hirabayashi, R Tsunoda, K Yonezawa, H Hori, M Yagi, M Arikawa, T Hashizume, R Ishiki, T Koizumi, K Nakayama, S Taguchi, M Nanasato, Y Yoshida, S Tsujiyama, T Nakamura, K Oku, M Shimizu, M Suwa, Y Momiyama, H Sugiyama, K Kobayashi, S Inoue, T Kadokami, K Maeno, K Kawamitsu, Y Maruyama, A Nakata, T Shibata, A Wada, H-J Cho, JO Na, B-S Yoo, J-O Choi, SK Hong, J-H Shin, M-C Cho, SH Han, J-O Jeong, J-J Kim, SM Kang, D-S Kim, MH Kim, G Llamas Esperon, J Illescas Díaz, P Fajardo Campos, J Almeida Alvarado, A Bazzoni Ruiz, J Echeverri Rico, I Lopez Alcocer, L Valle Molina, C Hernandez Herrera, C Calvo Vargas, FG Padilla Padilla, I Rodriguez Briones, EJJR Chuquiure Valenzuela, ME Aguilera Real, J Carrillo Calvillo, M Alpizar Salazar, JL Cervantes Escárcega, R Velasco Sanchez, N Al - Windy, L van Heerebeek, L Bellersen, H-P Brunner-La Rocca, J Post, GCM Linssen, M van de Wetering, R Peters, R van Stralen, R Groutars, P Smits, A Yilmaz, WEM Kok, P Van der Meer, P Dijkmans, R Troquay, AP van Alem, R Van de Wal, L Handoko, ICD Westendorp, PFMM van Bergen, BJWM Rensing, P Hoogslag, B Kietselaer, JA Kragten, FR den Hartog, A Alings, L Danilowicz-Szymanowicz, G Raczak, W Piesiewicz, W Zmuda, W Kus, P Podolec, W Musial, G Drelich, G Kania, P Miekus, S Mazur, A Janik, J Spyra, J Peruga, P Balsam, B Krakowiak, J Szachniewicz, M Ginel, J Grzybowski, W Chrustowski, P Wojewoda, A Kalinka, A Zurakowski, R Koc, M Debinski, W Fil, M Kujawiak, J Forys, M Kasprzak, M Krol, P Michalski, E Mirek-Bryniarska, K Radwan, G Skonieczny, K Stania, G Skoczylas, A Madej, J Jurowiecki, B Firek, B Wozakowska-Kaplon, K Cymerman, J Neutel, K Adams, P Balfour, A Deswal, A Djamson, P Duncan, M Hong, C Murray, D Rinde-Hoffman, S Woodhouse, R MacNevin, B Rama, C Broome-Webster, S Kindsvater, D Abramov, M Barettella, S Pinney, J Herre, A Cohen, K Vora, K Challappa, S West, S Baum, J Cox, S Jani, A Karim, A Akhtar, O Quintana, L Paukman, R Goldberg, Z Bhatti, M Budoff, E Bush, A Potler, R Delgado, B Ellis, J Dy, J Fialkow, R Sangrigoli, K Ferdinand, C East, S Falkowski, S Donahoe, R Ebrahimi, G Kline, B Harris, R Khouzam, N Jaffrani, N Jarmukli, N Kazemi, M Koren, K Friedman, W Herzog, J Silva Enciso, D Cheung, M Grover-McKay, P Hauptman, D Mikhalkova, V Hegde, J Hodsden, S Khouri, F McGrew, R Littlefield, P Bradley, B McLaurin, S Lupovitch, I Labin, V Rao, M Leithe, M Lesko, N Lewis, D Lombardo, S Mahal, V Malhotra, I Dauber, A Banerjee, J Needell, G Miller, L Paladino, K Munuswamy, M Nanna, E McMillan, M Mumma, M Napoli, W Nelson, T O'Brien, A Adlakha, A Onwuanyi, H Serota, J Schmedtje, A Paraschos, R Potu, C Sai-Sudhakar, M Saltzberg, A Sauer, P Shah, H Skopicki, H Bui, K Carr, G Stevens, N Tahirkheli, J Tallaj, K Yousuf, B Trichon, J Welker, P Tolerico, A Vest, R Vivo, X Wang, R Abadier, S Dunlap, N Weintraub, A Malik, P Kotha, V Zaha, G Kim, N Uriel, T Greene, A Salacata, R Arora, R Gazmuri, J Kobayashi, B Iteld, R Vijayakrishnan, R Dab, Z Mirza, V Marques, M Nallasivan, D Bensimhon, B Peart, H Saint-Jacques, K Barringhaus, J Contreras, A Gupta, S Koneru, V Nguyen, Verma, S, Dhingra, N, Butler, J, Anker, S, Ferreira, J, Filippatos, G, Januzzi, J, Lam, C, Sattar, N, Peil, B, Nordaby, M, Brueckmann, M, Pocock, S, Zannad, F, Packer, M, George, J, Jamal, W, Welty, F, Palmer, M, Clayton, T, Parhofer, K, Pedersen, T, Greenberg, B, Konstam, M, Lees, K, Carson, P, Doehner, W, Miller, A, Haas, M, Pehrson, S, Komajda, M, Anand, I, Teerlink, J, Rabinstein, A, Steiner, T, Kamel, H, Tsivgoulis, G, Lewis, J, Freston, J, Kaplowitz, N, Mann, J, Petrie, J, Perrone, S, Nicholls, S, Janssens, S, Bocchi, E, Giannetti, N, Zhang, J, Spinar, J, Seronde, M, Boehm, M, Merkely, B, Chopra, V, Senni, M, Taddi, S, Tsutsui, H, Choi, D, Chuquiure, E, La Rocca, H, Ponikowski, P, Juanatey, J, Squire, I, Pina, I, Bernstein, R, Cheung, A, Green, J, Kaul, S, Lip, G, Marx, N, Mccullough, P, Mehta, C, Rosenstock, J, Scirica, B, Shah, S, Wanner, C, Aizenberg, D, Cartasegna, L, Colombo Berra, F, Colombo, H, Fernandez Moutin, M, Glenny, J, Alvarez Lorio, C, Anauch, D, Campos, R, Facta, A, Fernandez, A, Ahuad Guerrero, R, Lobo Marquez, L, Leon de la Fuente, R, Mansilla, M, Hominal, M, Hasbani, E, Najenson, M, Moises Azize, G, Luquez, H, Guzman, L, Sessa, H, Amuchastegui, M, Salomone, O, Perna, E, Piskorz, D, Sicer, M, Perez de Arenaza, D, Zaidman, C, Nani, S, Poy, C, Resk, J, Villarreal, R, Majul, C, Smith Casabella, T, Sassone, S, Liberman, A, Carnero, G, Caccavo, A, Berli, M, Budassi, N, Bono, J, Alvarisqueta, A, Amerena, J, Kostner, K, Hamilton, A, Begg, A, Beltrame, J, Colquhoun, D, Gordon, G, Sverdlov, A, Vaddadi, G, Wong, J, Coller, J, Prior, D, Friart, A, Leone, A, Vervoort, G, Timmermans, P, Troisfontaines, P, Franssen, C, Sarens, T, Vandekerckhove, H, Van De Borne, P, Chenot, F, De Sutter, J, De Vuyst, E, Debonnaire, P, Dupont, M, Pereira Dutra, O, Canani, L, Vieira Moreira, M, de Souza, W, Backes, L, Maia, L, De Souza Paolino, B, Manenti, E, Saporito, W, Villaca Guimaraes Filho, F, Franco Hirakawa, T, Saliba, L, Neuenschwander, F, de Freitas Zerbini, C, Goncalves, G, Goncalves Mello, Y, Ascencao de Souza, J, Beck da Silva Neto, L, Da Silveira, J, de Moura Xavier Moraes Junior, J, de Souza Neto, J, Hernandes, M, Finimundi, H, Sampaio, C, Vasconcellos, E, Neves Mancuso, F, Noya Rabelo, M, Rodrigues Bacci, M, Santos, F, Vidotti, M, Simoes, M, Gomes, F, Vieira Nascimento, C, Precoma, D, Helfenstein Fonseca, F, Ribas Fortes, J, Leaes, P, Campos de Albuquerque, D, Kerr Saraiva, J, Rassi, S, Alves da Costa, F, Reis, G, Zieroth, S, Dion, D, Savard, D, Bourgeois, R, Constance, C, Anderson, K, Leblanc, M, Yung, D, Swiggum, E, Pliamm, L, Pesant, Y, Tyrrell, B, Huynh, T, Spiegelman, J, Lavoie, J, Hartleib, M, Bhargava, R, Straatman, L, Virani, S, Costa-Vitali, A, Hill, L, Heffernan, M, Khaykin, Y, Ricci, J, Senaratne, M, Zhai, A, Lubelsky, B, Toma, M, Yao, L, Mckelvie, R, Noronha, L, Babapulle, M, Pandey, A, Curnew, G, Lavoie, A, Berlingieri, J, Kouz, S, Lonn, E, Chehayeb, R, Zheng, Y, Sun, Y, Cui, H, Fan, Z, Han, X, Jiang, X, Tang, Q, Zhou, J, Zheng, Z, Zhang, X, Zhang, N, Zhang, Y, Shen, A, Yu, J, Ye, J, Yao, Y, Yan, J, Xu, X, Wang, Z, Ma, J, Li, Y, Li, S, Lu, S, Kong, X, Song, Y, Yang, G, Yao, Z, Pan, Y, Guo, X, Sun, Z, Dong, Y, Zhu, J, Peng, D, Yuan, Z, Lin, J, Yin, Y, Jerabek, O, Burianova, H, Fiala, T, Hubac, J, Ludka, O, Monhart, Z, Vodnansky, P, Zeman, K, Foldyna, D, Krupicka, J, Podpera, I, Busak, L, Radvan, M, Vomacka, Z, Prosecky, R, Cifkova, R, Durdil, V, Vesely, J, Vaclavik, J, Cervinka, P, Linhart, A, Brabec, T, Miklik, R, Bourhaial, H, Olbrich, H, Genth-Zotz, S, Kemala, E, Lemke, B, Bohm, M, Schellong, S, Rieker, W, Heitzer, T, Ince, H, Faghih, M, Birkenfeld, A, Begemann, A, Ghanem, A, Ujeyl, A, von Haehling, S, Dorsel, T, Bauersachs, J, Prull, M, Weidemann, F, Darius, H, Nickenig, G, Wilke, A, Sauter, J, Rauch-Kroehnert, U, Frey, N, Schulze, C, Konig, W, Maier, L, Menzel, F, Proskynitopoulos, N, Ebert, H, Sarnighausen, H, Dungen, H, Licka, M, Stellbrink, C, Winkelmann, B, Menck, N, Lopez-Sendon, J, de la Fuente Galan, L, Delgado Jimenez, J, Manito Lorite, N, Perez de Juan Romero, M, Galve Basilio, E, Cereto Castro, F, Gonzalez Juanatey, J, Gomez, J, Sanmartin Fernandez, M, Garcia-Moll Marimon, X, Pascual Figal, D, Bover Freire, R, Bonnefoy Cudraz, E, Jobbe Duval, A, Tomasevic, D, Habib, G, Isnard, R, Picard, F, Khanoyan, P, Dubois-Rande, J, Galinier, M, Roubille, F, Alexandre, J, Babuty, D, Delarche, N, Berneau, J, Girerd, N, Saxena, M, Rosano, G, Yousef, Z, Clifford, C, Arden, C, Bakhai, A, Boos, C, Jenkins, G, Travill, C, Price, D, Koenyves, L, Lakatos, F, Matoltsy, A, Noori, E, Zilahi, Z, Andrassy, P, Kancz, S, Simon, G, Sydo, T, Vorobcsuk, A, Kiss, R, Toth, K, Szakal, I, Nagy, L, Barany, T, Nagy, A, Szolnoki, E, Mandal, S, Rastogi, V, Shah, B, Mullasari, A, Shankar, J, Mehta, V, Oomman, A, Kaul, U, Komarlu, S, Kahali, D, Bhagwat, A, Vijan, V, Ghaisas, N, Mehta, A, Kashyap, J, Kothari, Y, Taddei, S, Scherillo, M, Zaca, V, Genovese, S, Salvioni, A, Fucili, A, Fedele, F, Cosmi, F, Volpe, M, Mazzone, C, Esposito, G, Doi, M, Yamamoto, H, Sakagami, S, Oishi, S, Yasaka, Y, Tsuboi, H, Fujino, Y, Matsuoka, S, Watanabe, Y, Himi, T, Ide, T, Ichikawa, M, Kijima, Y, Koga, T, Yuda, S, Fukui, K, Kubota, T, Manita, M, Fujinaga, H, Matsumura, T, Fukumoto, Y, Kato, R, Kawai, Y, Hiasa, G, Kazatani, Y, Mori, M, Ogimoto, A, Inoko, M, Oguri, M, Kinoshita, M, Okuhara, K, Watanabe, N, Ono, Y, Otomo, K, Sato, Y, Matsunaga, T, Takaishi, A, Miyagi, N, Uehara, H, Takaishi, H, Urata, H, Kataoka, T, Matsubara, H, Matsumoto, T, Suzuki, T, Takahashi, N, Imamaki, M, Yoshitama, T, Saito, T, Sekino, H, Furutani, Y, Koda, M, Shinozaki, T, Hirabayashi, K, Tsunoda, R, Yonezawa, K, Hori, H, Yagi, M, Arikawa, M, Hashizume, T, Ishiki, R, Koizumi, T, Nakayama, K, Taguchi, S, Nanasato, M, Yoshida, Y, Tsujiyama, S, Nakamura, T, Oku, K, Shimizu, M, Suwa, M, Momiyama, Y, Sugiyama, H, Kobayashi, K, Inoue, S, Kadokami, T, Maeno, K, Kawamitsu, K, Maruyama, Y, Nakata, A, Shibata, T, Wada, A, Cho, H, Na, J, Yoo, B, Choi, J, Hong, S, Shin, J, Cho, M, Han, S, Jeong, J, Kim, J, Kang, S, Kim, D, Kim, M, Llamas Esperon, G, Illescas Diaz, J, Fajardo Campos, P, Almeida Alvarado, J, Bazzoni Ruiz, A, Echeverri Rico, J, Lopez Alcocer, I, Valle Molina, L, Hernandez Herrera, C, Calvo Vargas, C, Padilla Padilla, F, Rodriguez Briones, I, Chuquiure Valenzuela, E, Aguilera Real, M, Carrillo Calvillo, J, Alpizar Salazar, M, Cervantes Escarcega, J, Velasco Sanchez, R, Al - Windy, N, van Heerebeek, L, Bellersen, L, Brunner-La Rocca, H, Post, J, Linssen, G, van de Wetering, M, Peters, R, van Stralen, R, Groutars, R, Smits, P, Yilmaz, A, Kok, W, Van der Meer, P, Dijkmans, P, Troquay, R, van Alem, A, Van de Wal, R, Handoko, L, Westendorp, I, van Bergen, P, Rensing, B, Hoogslag, P, Kietselaer, B, Kragten, J, den Hartog, F, Alings, A, Danilowicz-Szymanowicz, L, Raczak, G, Piesiewicz, W, Zmuda, W, Kus, W, Podolec, P, Musial, W, Drelich, G, Kania, G, Miekus, P, Mazur, S, Janik, A, Spyra, J, Peruga, J, Balsam, P, Krakowiak, B, Szachniewicz, J, Ginel, M, Grzybowski, J, Chrustowski, W, Wojewoda, P, Kalinka, A, Zurakowski, A, Koc, R, Debinski, M, Fil, W, Kujawiak, M, Forys, J, Kasprzak, M, Krol, M, Michalski, P, Mirek-Bryniarska, E, Radwan, K, Skonieczny, G, Stania, K, Skoczylas, G, Madej, A, Jurowiecki, J, Firek, B, Wozakowska-Kaplon, B, Cymerman, K, Neutel, J, Adams, K, Balfour, P, Deswal, A, Djamson, A, Duncan, P, Hong, M, Murray, C, Rinde-Hoffman, D, Woodhouse, S, Macnevin, R, Rama, B, Broome-Webster, C, Kindsvater, S, Abramov, D, Barettella, M, Pinney, S, Herre, J, Cohen, A, Vora, K, Challappa, K, West, S, Baum, S, Cox, J, Jani, S, Karim, A, Akhtar, A, Quintana, O, Paukman, L, Goldberg, R, Bhatti, Z, Budoff, M, Bush, E, Potler, A, Delgado, R, Ellis, B, Dy, J, Fialkow, J, Sangrigoli, R, Ferdinand, K, East, C, Falkowski, S, Donahoe, S, Ebrahimi, R, Kline, G, Harris, B, Khouzam, R, Jaffrani, N, Jarmukli, N, Kazemi, N, Koren, M, Friedman, K, Herzog, W, Silva Enciso, J, Cheung, D, Grover-McKay, M, Hauptman, P, Mikhalkova, D, Hegde, V, Hodsden, J, Khouri, S, Mcgrew, F, Littlefield, R, Bradley, P, Mclaurin, B, Lupovitch, S, Labin, I, Rao, V, Leithe, M, Lesko, M, Lewis, N, Lombardo, D, Mahal, S, Malhotra, V, Dauber, I, Banerjee, A, Needell, J, Miller, G, Paladino, L, Munuswamy, K, Nanna, M, Mcmillan, E, Mumma, M, Napoli, M, Nelson, W, O'Brien, T, Adlakha, A, Onwuanyi, A, Serota, H, Schmedtje, J, Paraschos, A, Potu, R, Sai-Sudhakar, C, Saltzberg, M, Sauer, A, Shah, P, Skopicki, H, Bui, H, Carr, K, Stevens, G, Tahirkheli, N, Tallaj, J, Yousuf, K, Trichon, B, Welker, J, Tolerico, P, Vest, A, Vivo, R, Wang, X, Abadier, R, Dunlap, S, Weintraub, N, Malik, A, Kotha, P, Zaha, V, Kim, G, Uriel, N, Greene, T, Salacata, A, Arora, R, Gazmuri, R, Kobayashi, J, Iteld, B, Vijayakrishnan, R, Dab, R, Mirza, Z, Marques, V, Nallasivan, M, Bensimhon, D, Peart, B, Saint-Jacques, H, Barringhaus, K, Contreras, J, Gupta, A, Koneru, S, Nguyen, V, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
- Subjects
Male ,medicine.medical_specialty ,Angiotensin receptor ,Glucoside ,Endocrinology, Diabetes and Metabolism ,[SDV]Life Sciences [q-bio] ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,Adrenergic beta-Antagonists ,Angiotensin-Converting Enzyme Inhibitors ,030204 cardiovascular system & hematology ,Placebo ,03 medical and health sciences ,Angiotensin Receptor Antagonists ,0302 clinical medicine ,Endocrinology ,Mineralocorticoid receptor ,Glucosides ,Double-Blind Method ,Internal medicine ,Post-hoc analysis ,Internal Medicine ,medicine ,Empagliflozin ,Humans ,030212 general & internal medicine ,Benzhydryl Compounds ,ComputingMilieux_MISCELLANEOUS ,Aged ,Benzhydryl Compound ,Heart Failure ,Ejection fraction ,business.industry ,Angiotensin Receptor Antagonist ,Adrenergic beta-Antagonist ,Angiotensin-Converting Enzyme Inhibitor ,Stroke Volume ,medicine.disease ,3. Good health ,Heart failure ,ACE inhibitor ,Female ,Hypotension ,business ,medicine.drug ,Human - Abstract
Contains fulltext : 249977.pdf (Publisher’s version ) (Closed access) BACKGROUND: It is important to evaluate whether a new treatment for heart failure with reduced ejection fraction (HFrEF) provides additive benefit to background foundational treatments. As such, we aimed to evaluate the efficacy and safety of empagliflozin in patients with HFrEF in addition to baseline treatment with specific doses and combinations of disease-modifying therapies. METHODS: We performed a post-hoc analysis of the EMPEROR-Reduced randomised, double-blind, parallel-group trial, which took place in 520 centres (hospitals and medical clinics) in 20 countries in Asia, Australia, Europe, North America, and South America. Patients with New York Heart Association (NYHA) classification II-IV with an ejection fraction of 40% or less were randomly assigned (1:1) to receive the addition of either oral empagliflozin 10 mg per day or placebo to background therapy. The primary composite outcome was cardiovascular death and heart failure hospitalisation; the secondary outcome was total heart failure hospital admissions. An extended composite outcome consisted of inpatient and outpatient HFrEF events was also evaluated. Outcomes were analysed according to background use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) or angiotensin receptor neprilysin inhibitors (ARNIs), as well as β blockers and mineralocorticoid receptor antagonists (MRAs) at less than 50% or 50% or more of target doses and in various combinations. This study is registered with ClinicalTrials.gov, NCT03057977. FINDINGS: In this post-hoc analysis of 3730 patients (mean age 66·8 years [SD 11·0], 893 [23·9%] women; 1863 [49·9%] in the empagliflozin group, 1867 [50·1%] in the placebo group) assessed between March 6, 2017, and May 28, 2020, empagliflozin reduced the risk of the primary outcome (361 in 1863 participants in the empagliflozin group and 462 of 1867 in the placebo group; HR 0·75 [95% CI 0·65-0·86]) regardless of background therapy or its target doses for ACE inhibitors or ARBs at doses of less than 50% of the target dose (HR 0·85 [0·69-1·06]) and for doses of 50% or more of the target dose (HR 0·67 [0·52-0·88]; p(interaction)=0·18). A similar result was seen for β blockers at doses of less than 50% of the target dose (HR 0·66 [0·54-0·80]) and for doses of 50% or more of the target dose (HR 0·81 [0·66-1·00]; p(interaction)=0·15). Empagliflozin also reduced the risk of the primary outcome irrespective of background use of triple therapy with an ACE inhibitor, ARB, or ARNI plus β blocker plus MRA (given combination HR 0·73 [0·61-0·88]; not given combination HR 0·76 [0·62-0·94]; p(interaction)=0·77). Similar patterns of benefit were observed for the secondary and extended composite outcomes. Empagliflozin was well tolerated and rates of hypotension, symptomatic hypotension, and hyperkalaemia were similar across all subgroups. INTERPRETATION: Empagliflozin reduced serious heart failure outcomes across doses and combinations of disease-modifying therapies for HFrEF. Clinically, these data suggest that empagliflozin might be considered as a foundational therapy in patients with HFrEF regardless of their existing background therapy. FUNDING: Boehringer Ingelheim and Eli Lilly and Company.
- Published
- 2022
46. The Geriatric Nutritional Risk Index and Prognostic Nutritional Index Predict the Overall Survival of Advanced Non-Small Cell Lung Cancer Patients
- Author
-
Shun Matsuura, Koshiro Ichijo, Yutaro Ito, Norimichi Akiyama, Tsutomu Kubota, Eisuke Mochizuki, Naoki Koshimizu, Masahiro Uehara, Keisuke Morikawa, Masanori Harada, and Masaru Tsukui
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Nutrition and Dietetics ,Index (economics) ,business.industry ,Medicine (miscellaneous) ,Prognosis ,medicine.disease ,Nutrition Assessment ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Nutritional risk index ,Overall survival ,medicine ,Humans ,Non small cell ,Lung cancer ,business ,Aged ,Retrospective Studies - Abstract
We aimed to assess the prognostic and predictive significance of pretreatment Geriatric Nutritional Risk Index (GNRI) and Prognostic Nutritional Index (PNI) measurements on advanced non-small cell lung cancer (NSCLC) patients treated with first-line therapy. Patients with advanced NSCLC treated between February 2014 and August 2020 were retrospectively analyzed. The optimal cutoff points for GNRI and PNI were measured with receiver operating characteristic (ROC) curve analysis according to overall survival (OS). The predictive factors for progression-free survival (PFS) and OS were evaluated with univariate and multivariate analyses via the Cox hazards regression. A total of 160 patients were included in the study. Significant differences between the low and high-GNRI or PNI groups were found regarding ECOG-PS. The low-GNRI and low-PNI groups had significantly shorter PFS and OS than the high-GNRI and high-PNI groups. A multivariate analysis using a Cox regression model revealed that the high-GNRI group was an independent prognostic factor of OS and PFS, and the PNI group was an independent prognostic factor of OS. Pretreatment GNRI and PNI may therefore be a potential effective predictor of the survival of advanced NSCLC patients undergoing first-line treatment.
- Published
- 2021
47. Early Prediction of a Serious Postoperative Course in Perihilar Cholangiocarcinoma
- Author
-
Shunsuke Onoe, Kay Uehara, Tsuyoshi Igami, Tomoki Ebata, Shoji Kawakatsu, Takashi Mizuno, Keitaro Matsuo, Nobuyuki Watanabe, Masato Nagino, Junpei Yamaguchi, and Yukihiro Yokoyama
- Subjects
medicine.medical_specialty ,business.industry ,Mortality rate ,Clinical course ,Disease ,Internal medicine ,Early prediction ,medicine ,Severe morbidity ,Surgery ,Trajectory analysis ,Perihilar Cholangiocarcinoma ,Complication ,business - Abstract
OBJECTIVE To visualize the postoperative clinical course using the comprehensive complication index (CCI) and to propose an early alarming sign for subsequent serious outcomes in perihilar cholangiocarcinoma. BACKGROUND Surgery for this disease carries a high risk of morbidity and mortality. The developmental course of the overall morbidity burden and its clinical utility are unknown. METHODS Patients who underwent major hepatectomy for perihilar cholangiocarcinoma between 2010 and 2019 were reviewed retrospectively. All postoperative complications were evaluated according to the Clavien-Dindo classification (CDC), and the CCI was calculated on a daily basis until postoperative day 14 to construct an accumulating graph as a trajectory. Group-based trajectory modeling was conducted to categorize the trajectory into clinically distinct patterns and the predictive power of early CCI for a subsequent serious course was assessed. RESULTS A total of 4230 complications occurred in the 484 study patients (CDC grade I, n=27; II, n=132; IIIa, n=290; IIIb, n=4; IVa, n=21; IVb, n=1; and V, n=9). The trajectory was categorized into 3 patterns: mild (n=209), moderate (n=235), and severe (n=40) morbidity courses. The 90-day mortality rate significantly differed among the courses: 0%, 0.9%, and 17.5%, respectively (P
- Published
- 2021
48. Which factors have a great impact on coagulopathy and hemostatic impairment after cardiopulmonary bypass in cardiovascular surgery? An analysis based on rotational thromboelastometry
- Author
-
Takuya Tsusue, Kenshi Yoshimura, Hirotsugu Hamamoto, Hiroki Sato, Norio Itai, Shinji Miyamoto, Hideo Iwasaka, Takafumi Abe, Satomi Tahara, and Shuichiro Uehara
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Hemostatics ,Fibrin ,law.invention ,A10 ,Coagulopathy ,law ,Rotational thromboelastometry ,medicine ,Cardiopulmonary bypass ,Humans ,Multiple linear regression analysis ,Retrospective Studies ,Cardiopulmonary Bypass ,biology ,business.industry ,General Medicine ,Perioperative ,Blood Coagulation Disorders ,medicine.disease ,Thrombelastography ,Surgery ,Cardiac surgery ,Thromboelastometry ,Clotting time ,Cardiothoracic surgery ,biology.protein ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Objectives This study aimed to investigate which factors have a great impact on coagulopathy after cardiopulmonary bypass (CPB) using rotational thromboelastometry (ROTEM)., Methods Ninety-eight patients undergoing cardiovascular surgery using CPB were enrolled. Data of amplitude 10 min after clotting time (A10) of ROTEM measured routinely before and after CPB were retrospectively collected. ROTEM has some assays by which we can evaluate the capacity of extrinsic coagulation (EXTEM), intrinsic coagulation (INTEM), fibrin polymerization (FIBTEM), and the effect of heparin (HEPTEM). The platelet component, defined as PLTEM, can be calculated by subtracting FIBTEM from EXTEM. Age, sex, total plasma volume, pre-CPB A10, lowest body temperature, in–out balance during CPB, intraoperative bleeding amount, and type of pumps were considered as possible factors. Univariate and multivariate analyses were performed for the rate of change of A10., Results The change rate of each A10 had a significant negative correlation with bleeding amount (p < 0.01 for EXTEM; p < 0.01 for INTEM; p = 0.02 for FIBTEM; p < 0.01 for PLTEM). Female sex was a significant contributive predictor for the greater decline of EXTEM (p < 0.01) and INTEM (p < 0.01); positive balance for EXTEM (p < 0.01), FIBTEM (p = 0.01), and PLTEM (p < 0.01); long CPB time for INTEM (p = 0.01); centrifugal pump for FIBTEM (p < 0.01); and large pre-CPB A10 for PLTEM (p < 0.01)., Conclusion In perioperative hemostatic management using ROTEM, attention should be given to the effects of these multiple factors.
- Published
- 2021
49. Palliative care physicians’ recognition of patients after immune checkpoint inhibitors and immune-related adverse events
- Author
-
Mitsunori Miyashita, Kazuhiro Kosugi, Takashi Kawaguchi, Masashi Kato, Miyuki Sone, Tatsuya Morita, Toshifumi Kosugi, Takuhiro Yamaguchi, Yuko Usui, Akio Mizushima, Yuko Uehara, Eriko Satomi, Yoshihisa Matsumoto, Tomofumi Miura, and Naoki Nakamura
- Subjects
medicine.medical_specialty ,Palliative care ,Cross-sectional study ,business.industry ,Immune checkpoint inhibitors ,Nursing research ,Pain medicine ,Palliative Care ,Clinical Practice ,Cross-Sectional Studies ,Immune system ,Japan ,Oncology ,Physicians ,Emergency medicine ,medicine ,Humans ,Adverse effect ,business ,Immune Checkpoint Inhibitors - Abstract
This study investigated the experience of palliative care physicians (PCPs) and their knowledge and recognition of immune checkpoint inhibitors (ICIs) and immune-related adverse events (irAEs) in clinical practice as well as the need to provide palliative care services for patients after ICI treatments. A cross-sectional survey with self-administered questionnaires was conducted between February and April 2020. A total of 759 questionnaires were sent to PCPs in Japan. The changes in the PCPs’ knowledge and recognition of ICIs and irAEs due to the increased experiences of treating patients after ICI treatments were analyzed. Four hundred ninety-two responses (64.8%) were analyzed. Only 15.0% of respondents had no experience of patients after ICI treatments, while 53.9% had experience of more than six patients. On the other hand, 40% of respondents had no experience of patients with suspected irAEs, while only 13.4% had experience of more than six patients. Respondents with more experience of patients after ICI treatments or those with suspected irAEs had extensive knowledge of ICIs and irAEs, were more confident in treating these patients, and tended to consider irAEs as therapeutic indications. The majority of respondents required guidelines and efficient consultation systems with oncologists. This study demonstrated that PCPs with experience had extensive knowledge and confidence of ICIs and irAEs and tended to recognize irAEs as therapeutic indications. The establishment of a more intimate relationship between PCPs and oncologists is important for providing better treatment for these patients.
- Published
- 2021
50. Relationship between the presence of primary care physicians and health‐related quality of life
- Author
-
Tomoko Tsukamoto, Yoshiyuki Ohira, Akiko Ikegami, Takanori Uehara, Masatomi Ikusaka, Kiyoshi Shikino, Kazutaka Noda, and Daiki Yokokawa
- Subjects
Health related quality of life ,medicine.medical_specialty ,business.industry ,Family medicine ,Internal Medicine ,medicine ,Health services research ,Primary care ,Geriatrics and Gerontology ,Family Practice ,business ,Health policy - Abstract
The supply of primary care physicians is associated with better health outcomes and a lower total cost of health services. However, the effect of the presence or absence of primary care physicians on health-related quality of life (QOL) is unknown. We comparatively investigated the health-related QOL of ordinary citizens according to the presence or absence of a primary care physician.We conducted an observational cross-sectional study using a propensity score analysis. A questionnaire on health-related QOL (SF-36v2, age, gender, presence or absence of a primary care physician, and chronic disease status) was mailed to 2200 individuals identified through stratified random sampling. We used propensity scores to compensate for covariates and analyzed three component SF-36 summary scores and subscale scores of the "primary care physician" and "no primary care physician" groups.Valid responses were received from 1095 individuals (49.8%). The "primary care physician group" comprised 653 individuals (59.6%). The physical health component scores of the "primary care physician group" were significantly lower than those of the "no primary care physician group," and the "mental health component" scores were significantly higher (Patients who had a primary care physician with whom they could comfortably consult at any time had a high mental health component score, and low physical health component score in the health-related QOL.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.